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Summary 
 
A clinical trial was undertaken using three different inhalant anaesthetic agents 
and one intravenous anaesthetic agent in dogs undergoing routine desexing surgery.  
Healthy adult dogs undergoing either ovariohysterectomy or castration were 
assessed as to their demeanour, with the more excitable dogs being placed in groups 
receiving premedication with acepromazine and morphine. All dogs were then 
randomly assigned an anaesthetic agent for induction of general anaesthesia. The 
agents were the inhalants halothane, isoflurane and sevoflurane, and the intravenous 
agent propofol. Inhalant inductions were undertaken using a tight fitting mask 
attached to a standard anaesthetic machine with a rebreathing circuit, with the 
maximum dose of inhalant available from a standard vaporiser. Propofol inductions 
were undertaken via intravenous catheter. Dogs induced with propofol were randomly 
assigned one of the three inhalant agents for maintenance. Those induced by inhalant 
agent were maintained using the same agent. The surgical procedure was undertaken 
in standard fashion, as was recovery from anaesthesia. All dogs received the non-
steroidal anti-inflammatory agent meloxicam. 
Data collection was divided into three stages: induction, maintenance, and 
recovery from anaesthesia. Variables measured at induction of anaesthesia were time 
to intubation, number of intubation attempts, tolerance of mask, quality of induction 
and quality of transfer to the maintenance stage. Standard variables for monitoring of 
anaesthesia were recorded throughout the maintenance of anaesthesia. Variables 
measured at recovery were time to righting, time to standing and quality of recovery. 
The mean time to intubation when using the newer inhalant sevoflurane (196.2 
± 14.8sec, mean ± SE) was not significantly different to that for halothane (221.4 ± 
14.0sec) or isoflurane (172.4 ± 15.0sec). Time to intubation with isoflurane was 
significantly faster than with halothane. Mean time to intubation with propofol (85.4 ± 
7.7sec) was significantly faster than that for any of the three inhalants. Choice of 
inhalant had no effect on quality of induction. The use of premedication significantly 
improved the quality of induction.  The use of propofol for induction likewise 
significantly improved the quality of induction.  
v 
Standard cardiorespiratory variables measured during the maintenance phase 
of anaesthesia remained within normal clinical ranges for all three inhalants, and were 
therefore not further analysed.  
Choice of inhalant agent had no significant effect on the time to righting or 
standing in recovery. The use of propofol for induction had no effect on these 
variables. Animals placed in groups receiving premedication had significantly longer 
times to righting and standing. The oesophageal temperature at the end of the 
procedure had a significant effect on times to righting and standing, with lower 
temperatures contributing to slower recoveries. Independent of procedure time, male 
dogs had shorter times to righting than female dogs. 
 
 
 
vi 
Table of Contents 
 
A CLINICAL STUDY OF INHALANT ANAESTHESIA IN DOGS..............i 
Summary..........................................................................................................iv 
Table of Contents ............................................................................................vi 
List of Tables ....................................................................................................x 
List of Figures..................................................................................................xi 
List of Abbreviations .....................................................................................xii 
Introduction......................................................................................................1 
Chapter 1: Literature Review.........................................................................5 
1.1 Inhalant anaesthetics ................................................................................6 
1.1.1 History...............................................................................................6 
1.1.2 Chemical composition ......................................................................6 
1.1.3 Method of action ...............................................................................7 
1.1.4 Therapeutic effects............................................................................8 
1.1.4.1 Dose requirements .....................................................................8 
1.1.4.2 Factors affecting induction of anaesthesia .................................9 
1.1.4.3 Recovery from anaesthesia ......................................................12 
1.1.5 Side effect profile............................................................................12 
1.1.5.1 Effects on cerebral function .....................................................12 
1.1.5.2 Effects on the cardiovascular system.......................................13 
1.1.5.2.1 Effects on heart rate ..........................................................13 
1.1.5.2.2 Effects on cardiac rhythm .................................................14 
1.1.5.2.3 Effects on cardiac contractility .........................................14 
1.1.5.2.4 Effects on diastolic function .............................................15 
1.1.5.2.5 Effects on vasculature .......................................................15 
1.1.5.2.5.1 Systemic vasculature..................................................15 
1.1.5.2.5.2 Coronary vasculature .................................................15 
1.1.5.2.5.3 Cerebral vasculature...................................................16 
1.1.5.2.6 Effects on blood pressure..................................................16 
1.1.5.3 Effects on the Respiratory System...........................................16 
1.1.5.3.1 Odour and Irritancy...........................................................16 
1.1.5.3.2 Respiratory effects post-induction ....................................17 
1.1.5.4 Effects on renal function..........................................................18 
1.1.5.5 Effects on the liver ...................................................................19 
1.1.6 Hazards of occupational exposure ..................................................20 
1.1.7 Environmental effects .....................................................................20 
1.2 Propofol..................................................................................................22 
1.2.1 Composition....................................................................................22 
1.2.2 Pharmacokinetics ............................................................................22 
1.2.3 Metabolism .....................................................................................23 
1.2.4 Induction of and recovery from anaesthesia ...................................23 
1.2.5 Side effects profile ..........................................................................24 
1.2.5.1 Cardiovascular effects..............................................................24 
1.2.5.2 Respiratory effects ...................................................................24 
1.2.5.3 Proconvulsant/anticonvulsant effects.......................................25 
1.3 Acepromazine ........................................................................................26 
1.3.1 Introduction.....................................................................................26 
1.3.2 Method of action .............................................................................26 
vii 
1.3.3 Therapeutic effects..........................................................................26 
1.3.4 Side effects profile ..........................................................................27 
1.4 Morphine................................................................................................29 
1.4.1 History and derivation.....................................................................29 
1.4.2 Pharmacology .................................................................................29 
1.4.3 Therapeutic effects..........................................................................30 
1.4.4 Side effects profile ..........................................................................30 
1.5 Meloxicam .............................................................................................32 
1.6 Conclusion .............................................................................................34 
Chapter 2: Materials and Methods ..............................................................36 
2.1 Study Objectives ....................................................................................37 
2.2 Experimental design...............................................................................37 
2.3 Anaesthesia protocols ............................................................................39 
2.3.1 Premedication .................................................................................39 
2.3.2 Intravenous catheterisation .............................................................39 
2.3.3 Induction protocols .........................................................................40 
2.3.3.1 Inhalant agent inductions .........................................................40 
2.3.3.2 Intravenous agent inductions ...................................................44 
2.3.4 Maintenance of anaesthesia ............................................................46 
2.3.5 Recovery .........................................................................................47 
2.3.5.1 Supplementary analgesia .........................................................48 
2.4 Surgery...................................................................................................48 
2.5 Data Collection ......................................................................................49 
2.5.1 Prior to anaesthesia .........................................................................49 
2.5.1.1 Quantitative data ......................................................................49 
2.5.1.1.1  General health status ........................................................49 
2.5.1.2 Qualitative data ........................................................................49 
2.5.1.2.1 Demeanour ........................................................................49 
2.5.1.2.2 Sedation.............................................................................50 
2.5.2 During induction of general anaesthesia.........................................50 
2.5.2.1 Quantitative data ......................................................................50 
2.5.2.1.2 Time to intubation.............................................................51 
2.5.2.1.3 Intubation attempts............................................................51 
2.5.2.1.4 Dose of propofol prior to intubation .................................52 
2.5.2.1.5 Dose of propofol post-intubation ......................................52 
2.5.2.2 Qualitative data ........................................................................52 
2.5.2.2.1 Tolerance of mask.............................................................52 
2.5.2.2.2 Quality of induction ..........................................................53 
2.5.2.2.3 Quality of transfer .............................................................53 
2.5.3 During maintenance of anaesthesia ................................................54 
2.5.3.1 Quantitative data ......................................................................54 
2.5.3.1.1 Cardiovascular variables ...................................................54 
2.5.3.1.2 Respiratory variables.........................................................55 
2.5.3.1.3 Temperature ......................................................................56 
2.5.3.1.4 Frequency of data collection .............................................56 
2.5.3.1.5 Other quantitative data ......................................................56 
2.5.3.2 Qualitative data ........................................................................57 
2.5.4 Recovery from anaesthesia .............................................................57 
2.5.4.1 Quantitative data ......................................................................57 
2.5.4.1.1 Time of extubation............................................................57 
viii 
2.5.4.1.2 Time to righting ................................................................57 
2.5.4.1.3 Time to standing ...............................................................57 
2.5.4.2 Qualitative data ........................................................................57 
2.5.4.2.1 Quality of recovery ...........................................................57 
2.6 Statistical Analysis.................................................................................58 
2.6.1 Time to intubation...........................................................................58 
2.6.2 Quality of induction ........................................................................59 
2.6.3 Propofol dose for induction ............................................................59 
2.6.4 Time to righting ..............................................................................59 
2.6.5 Time to standing .............................................................................59 
2.7 Costing of agents....................................................................................59 
Chapter 3: Results..........................................................................................61 
3.1 Cases enrolled ........................................................................................62 
3.2 Group allocation.....................................................................................62 
3.3 Prior to induction of anaesthesia............................................................63 
3.4 Induction of anaesthesia.........................................................................63 
3.4.1 Inhalant inductions..........................................................................63 
3.4.2 Intravenous inductions ....................................................................64 
3.4.2.1 Propofol dose requirements .....................................................64 
3.4.3 Intubation attempts..........................................................................64 
3.4.4 Time to intubation...........................................................................65 
3.4.5 Quality of induction ........................................................................67 
3.5  Intraoperative Variables........................................................................67 
3.6 Recovery from anaesthesia ....................................................................76 
3.6.1 Time to righting ..............................................................................76 
3.6.2 Time to standing .............................................................................76 
3.7 Cost of induction and maintenance of anaesthesia ................................77 
Chapter 4: Discussion ....................................................................................79 
4.1 Introduction............................................................................................80 
4.2 Experimental design...............................................................................80 
4.3 The clinical environment .......................................................................81 
4.4 Induction of anaesthesia.........................................................................83 
4.4.1 Time to induction............................................................................83 
4.4.1.1 Introduction..............................................................................83 
4.4.1.2 Definition .................................................................................83 
4.4.1.3 Experimental group size ..........................................................84 
4.4.1.4 Intravenous inductions .............................................................84 
4.4.1.5 Halothane dosage .....................................................................84 
4.4.1.6 Failed inhalant inductions ........................................................85 
4.4.1.7 Effect of premedication............................................................86 
4.4.1.8 Clinical significance.................................................................87 
4.4.2 Quality of induction ........................................................................88 
4.4.2.1 Measuring quality ....................................................................88 
4.4.2.2 Effect of premedication............................................................89 
4.4.2.3 Intravenous inductions .............................................................89 
4.5 Recovery ................................................................................................89 
4.5.1 Introduction.....................................................................................89 
4.5.2 Time to righting and standing .........................................................90 
4.5.2.1 Duration of anaesthesia............................................................90 
4.5.2.2 Choice of induction agent ........................................................90 
ix 
4.5.2.3 Effect of premedication............................................................91 
4.5.2.4 Effect of body temperature ......................................................91 
4.6 Intra-anaesthesia variables .....................................................................92 
4.6.1 Biological significance....................................................................92 
4.6.2 Heart rate.........................................................................................93 
4.6.3 End-tidal carbon dioxide concentration ..........................................93 
4.6.4 Mean arterial blood pressure...........................................................94 
4.6.5 End-tidal inhalant anaesthetic agent concentration.........................95 
4.7 Financial considerations.........................................................................96 
4.8 Conclusion .............................................................................................97 
Chapter 5: References ...................................................................................99 
 
 
x 
 
List of Tables 
 
         Page 
 
Table 1.1 Selected, relevant chemical data for halothane, 7 
isoflurane and sevoflurane 
 
Table 1.2 Canine dose requirements for inhalant  9 
  anaesthetics 
 
Table 2.1 Experimental groups     38 
   
Table 3.1 Experimental group allocation   62 
 
Table 3.2 Time to intubation     66 
 
Table 3.3 Quality of induction scores    67 
  
Table 3.4 Intraanaesthesia variables    69 
 
 
 
 
xi 
 
List of Figures 
 
 
         Page 
 
Figure 3.1 Time to intubation, in minutes   66 
 
Figure 3.2  Heart rate in dogs anaesthetised using halothane,  70 
isoflurane and sevoflurane, with and without  
premedication 
 
Figure 3.3 Mean arterial pressure in dogs anaesthetised  71 
using halothane, isoflurane and sevoflurane,  
with and without premedication 
 
 
Figure 3.4 Mean end-tidal carbon dioxide    72 
concentrations in dogs anaesthetised using  
halothane, isoflurane and sevoflurane,  
with and without premedication 
 
Figure 3.5 Mean end-tidal inhalant anaesthetic    73 
concentrations (vol%) in dogs anaesthetised  
using halothane, isoflurane and sevoflurane,  
with and without premedication 
 
Figure 3.6 Mean end-tidal inhalant anaesthetic    74 
concentrations (MAC multiples) in dogs  
anaesthetised using halothane, isoflurane and  
sevoflurane, with and without premedication 
 
Figure 3.7 Oesophageal temperature at end procedure   75 
and its effect on recovery, in terms of time  
to righting 
 
Figure 3.8 Effect of premedication on recovery from  77 
  anaesthesia 
xii 
 
List of Abbreviations 
 
ACP  Acepromazine  
ANOVA Analysis of variance  
A$  Australian dollars 
Br  Bromine 
BP  Barometric pressure 
CBF  Cerebral blood flow  
°C  Degrees Celsius 
CaEDTA Calcium ethylene diaminetetraacetic acid  
CDC  Canine Desexing Clinic 
CI  Confidence interval 
Cl  Chlorine 
cmH2O Centimetres of water  
CMRO2 Cerebral metabolic requirement for oxygen 
CNS  Central nervous system  
CO2  Carbon dioxide  
COX-1 Cyclo-oxygenase isoform 1 
COX-2 Cyclo-oxygenase isoform 2 
dP/dt  Rate of change of pressure over time 
drops.ml-1 Drops per millilitre  
ED95  Estimated dose (95%) 
EDTA  Ethylene diaminetetraacetic acid 
ECG   Electrocardiogram 
EEG  Electroencephalogram 
ETA  End-tidal inhalant anaesthetic concentration  
F  Fluorine 
G  Gauge  
GST   Goods and services tax 
GWP  Greenhouse Warming Potential 
Hal  Halothane 
hr  Hour  
xiii 
ICP  Intracranial pressure  
Iso  Isoflurane 
IU.ml-1 International units per millilitre 
IM  Intramuscular 
kg  Kilogram 
l.min-1  Litres per minute 
m  Metre 
MAC  Minimum alveolar concentration 
MAP  Mean arterial pressure 
mg.kg-1 Milligrams per kilogram 
ml.kg.min-1 Millilitres per kilogram per minute 
mg.ml-1 Milligrams per millilitre 
min  Minute 
mmHg  Millimetres of mercury  
ml.min-1 Millilitres per minute 
ml.sec-1 Millilitres per second 
ng.ml-1  Nanograms per millilitre 
NSAID Non-steroidal anti-inflammatory drug 
O2  Oxygen 
ODP   Ozone Depletion Potential 
OR  Odds ratio 
PA  Alveolar partial pressure 
PV  Venous partial pressure 
Pro  Propofol 
Q  Cardiac output 
SC  Subcutaneous 
SD  Standard deviation 
SE  Standard error 
sec  Second 
Sevo  Sevoflurane 
SpO2  Haemoglobin oxygen saturation 
g.ml-1  Micrograms per millilitre 
  Blood:gas solubility 
 
1 
Introduction 
 
Inhalation was the only means of delivery of agents for general anaesthesia for 
almost one hundred years. Whilst indications for the use of intravenous anaesthetics 
have developed in more recent years, inhalant agents remain widely used in human 
and veterinary anaesthesia (Steffey 1996). The value of inhalants lies in their 
flexibility and predictability; primarily for maintenance of anaesthesia, but also for 
induction. 
The development of halothane in the early 1950’s represented a significant 
progression in inhalant anaesthesia. Its fluorinated alkane structure produced a volatile 
liquid that was non-flammable, and considerably less toxic to the patient than older 
agents such as diethyl ether (Steffey 1996; Fee and Thompson 1997). However, its 
side effect profile, and specifically its ability to occasionally produce a fatal acute 
hepatitis in the human, encouraged the pursuit of superior agents. Isoflurane and 
sevoflurane were products of this search. Isoflurane, introduced into commercial use 
in the 1970’s, was significantly less soluble in blood than halothane, and was free of 
the hepatic side effects. It possessed, unfortunately, a notably more irritating smell 
than halothane. Sevoflurane, although first synthesised in the 1970’s, was not released 
in the US until 1995. It is even less soluble in blood than isoflurane, and has a less 
irritating odour (Brown 1995; Sinha et al. 1996).  
Little is known about the method of action of inhalant anaesthetics. It appears 
likely that immobility is mediated through the action of the agent on the motor 
interneurons of the spinal cord (Rampil and King 1996), as removal of the entire 
cerebrum and brainstem does not reduce the inhalant anaesthetic dose requirement to 
prevent movement in response to stimulus (Rampil et al. 1993). It is suggested that 
the inability to recall events under anaesthesia may be due to effects of the inhalant on 
higher centres of the brain (Koblin 1994; Eger et al. 2002).  
Induction of anaesthesia with inhalant agents is dependent upon the interplay 
of several factors. Increasing cardiac output, minute respiratory volume or the 
gradient between the alveolar concentration and arterial concentration will increase 
the speed of induction. Whilst manipulation of cardiac output may be infeasible at the 
point of induction of anaesthesia, minute respiratory volume may be influenced by the 
method of inhalant induction and the smell of the inhalant, and the slope of the 
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concentration gradient is influenced by the inhalant vaporiser settings and gas flow 
rates used (Eger 1974). A small number of studies have compared the speed and 
quality of induction of anaesthesia using the modern inhalant agents in the dog. 
Equipotent doses of 2.0.MAC of isoflurane and sevoflurane delivered a significantly 
more rapid time to intubation for sevoflurane than isoflurane (Johnson et al. 1998). 
Doses of 2.5.MAC produced similar results, with sevoflurane significantly faster to 
intubation than isoflurane, which in turn was significantly faster than halothane 
(Mutoh et al. 1995). However, standard practice in many veterinary practices is to use 
the maximum dose of the inhalant available from a standard vaporiser, which is in 
excess of 3.0.MAC, particularly for halothane. A previous study examined induction 
of anaesthesia using halothane and isoflurane at close to maximum vaporiser output, 
revealing no significant differences in induction speed (Hellebrekers 1986). Recovery 
from anaesthesia is reliant on the same factors as induction. Dogs anaesthetised with 
halothane recovered to standing slower than those anaesthetised with isoflurane in an 
experimental study (Hellebrekers 1986). A similar study of recovery from anaesthesia 
using isoflurane or sevoflurane could elucidate no differences between the two agents 
(Johnson et al. 1998).  
Whilst the newer inhalants have overcome the acute hepatitis occasionally 
associated with halothane, all three agents do have effects on several body systems 
which are not beneficial. There are case reports in the human literature of seizure 
activity associated with sevoflurane anaesthesia (Adachi et al. 1992; Terasako and 
Ishii 1996; Woodforth et al. 1997; Kaisti et al. 1999; Iijima et al. 2000), although 
similar problems have not been revealed in the dog (Scheller et al. 1990). Halothane 
anaesthesia causes a greater increase in ICP and CBF than that occurring with the two 
newer inhalants, which may retain these values within normal limits (Scheller et al. 
1990; Kuroda et al. 1997; Monkhoff et al. 2001). 
All three inhalants have important effects on the cardiovascular system. 
Halothane’s ability to sensitise the heart to catecholamine-induced arrhythmias was a 
strong motivation for further development of the fluorinated alkane inhalant 
anaesthetics (Wallin et al. 1975; Steffey 1995). The adrenaline concentrations 
required to cause cardiac arrhythmias in the dog are far higher with isoflurane and 
sevoflurane than with halothane. All three agents decrease cardiac output (Steffey and 
Howland 1978; Bernard et al. 1992; Mutoh et al. 1997), halothane being somewhat 
more depressive of CO than isoflurane or sevoflurane. The three inhalants are 
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significant vasodilators (Malan et al. 1995; Holzman et al. 1996). Although greater 
vasodilation with the two newer inhalants leads to slightly lower MAP values than 
with halothane, statistically significant differences have not been demonstrated in 
several studies (Bernard et al. 1990; Frink et al. 1992a; Harkin et al. 1994; Malan et 
al. 1995; Mutoh et al. 1995).  
Of the three agents, isoflurane is the most irritant to the respiratory tract, 
followed by halothane, with sevoflurane being the most benign (Doi and Ikeda 1993). 
This may well impact on the relative suitability of the three agents for induction of 
anaesthesia. All three cause depression of ventilation in the anaesthetised patient, 
isoflurane and sevoflurane both causing greater depression than halothane (Mutoh et 
al. 1995; Mutoh et al. 1997).  
The development of sevoflurane was delayed by concerns that fluoride ions, 
produced by metabolism of the agent, and a polyvinyl ether, arising from interaction 
of the agent with carbon dioxide absorbents, would be deleterious to renal function in 
the patient (Brown 1995). Whilst this appeared to be an issue in rats, no strong 
evidence of kidney dysfunction has been found in humans following sevoflurane 
anaesthesia (Patel and Goa 1996). None of the three agents produce changes in renal 
blood flow (Gelman et al. 1984; Crawford et al. 1992). However, blood flow to the 
liver is reduced, although this is not thought to be of consequence in the absence of 
other complicating factors (Steffey 1995).  
The objectives of the current study were to investigate the speed and quality of 
anaesthetic induction and recovery using the three inhalants. This was to be carried 
out in the clinical domain. Whilst previous research in the human field has thoroughly 
compared the inhalants in the clinical domain, as summarised by Patel and Goa 
(1996), the veterinary literature is restricted almost entirely to the experimental 
situation; clinical veterinary studies have only been of a qualitative or non-
comparative nature (Mutoh et al. 1995; Johnson et al. 1998; Tzannes et al. 2000; 
Haitjema and Cullen 2001).  
Inhalant agents are not the most common agents used for induction of 
anaesthesia in private veterinary practice, with the use of intravenous anaesthetic 
agents more popular (Nicholson and Watson 2001). Propofol is a relatively new 
intravenous agent, having been first synthesised in the 1970s (Reves et al. 1994). It is 
attractive due to the generally high quality of the induction associated with its use 
(Weaver and Raptopoulos 1990; Zoran et al. 1993), and its ability to be metabolised 
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outside of the liver (Veroli et al. 1992). Induction is rapid, and recovery from a single 
induction bolus is adjudged complete within approximately 20min (Watkins et al. 
1987). A reduction in cardiac output of approximately 20% occurs during induction 
with propofol (Brussel et al. 1989), persisting for less than 5min. A period of apnoea 
lasting approximately 30sec is often associated with induction (Watkins et al. 1987; 
Morgan and Legge 1989; Zoran et al. 1993), although the related rise in arterial CO2 
is mild in biological terms (Robertson et al. 1992). Paradoxically, propofol is noted to 
have both proconvulsant and anticonvulsant properties, with trembling and tonic-
clonic type activity often noted at induction (Weaver and Raptopoulos 1990; 
Robertson et al. 1992). No published studies have compared the induction of 
anaesthesia with propofol to that of inhalant agents in the veterinary clinical situation. 
Premedication is commonly used in veterinary practice to decrease the dose of 
induction agent required, to provide analgesia and to increase the quality of induction 
and maintenance of anaesthesia (Thurmon et al. 1996). Acepromazine and morphine 
provides a suitable neuroleptanalgesic combination for these purposes (Thurmon et al. 
1996). For those animals undergoing invasive surgery without the benefit of such 
premedication, some form of postoperative analgesia is important. This may be 
provided by perioperative use of a non-steroidal anti-inflammatory drug such as 
meloxicam.  
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1.1 Inhalant anaesthetics 
1.1.1 History 
The earliest agents used for general anaesthesia – nitrous oxide and diethyl 
ether – were delivered by inhalation, and inhalant agents retain great popularity. 
Being administered and eliminated by the respiratory tract allows predictable and 
rapid adjustment of depth of anaesthesia. The most common inhalants used in clinical 
veterinary practice today are halothane and isoflurane (Nicholson and Watson 2001). 
Sevoflurane shows potential for supplanting the use of these two agents. 
Halothane is the oldest of these three agents, being first synthesised in the 
early 1950’s (Steffey 1996). The ability to commercially produce fluorinated alkanes 
(Section 1.1.2) such as halothane was in fact a fortuitous byproduct of the Manhattan 
Project (Fee and Thompson 1997). Halothane represented a quantum progression 
from previous inhaled agents such as ether and chloroform, in being non-flammable 
and considerably less toxic. However, unfavourable side effects in clinical use 
encouraged further development, and isoflurane and sevoflurane were both first 
synthesised in the late 1960’s (Brown 1995). Commercial indifference and questions 
regarding its metabolism and stability stalled further development of sevoflurane, 
whilst isoflurane was introduced to human anaesthesia practice in the mid 1970’s 
(Steffey 1995). Isoflurane was registered for veterinary use in Australia in 2001. 
Eventually resurrected by a Japanese pharmaceutical company in 1988, sevoflurane 
was licensed for human use in that country in 1990, several years before its 
introduction elsewhere (Brown 1995). Sevoflurane was registered for veterinary use 
in the USA in 2001, but is currently not registered for veterinary use in Australia.  
 
1.1.2 Chemical composition 
With the exception of nitrous oxide, all the “modern” inhalant anaesthetics are 
halogenated organic compounds. The addition of the halogens chlorine, bromine or 
fluorine to simple short chain hydrocarbons creates anaesthetic agents which are more 
potent, less biologically reactive and less flammable than their non-halogenated 
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counterparts (Steffey 1995). The addition of an ether linkage, as occurs in the 
composition of isoflurane and sevoflurane, decreases the cardiac arrhythmogenicity of 
the agent (Section 1.1.5.2.2). The use of fluorine over other halogens produces lower 
potency but greater stability (Steffey 1996). 
Relevant chemical data for halothane, isoflurane and sevoflurane is presented 
in Table 1.1. All three are liquid at room temperature and pressure, with vapour 
pressures sufficiently high to produce a vapour concentration able to induce general 
anaesthesia when inhaled. A small quantity of a preservative, thymol, is added to 
halothane to prolong its shelf life, as it is less stable than its more fluorinated 
competitors.   
 
 Halothane Isoflurane Sevoflurane 
Boiling point (°C) 50 49 59 
Vapour pressure (mmHg, 20°C) 243 240 160 
Blood:gas solubility coefficient (37°C) 2.54 1.46 0.60 
Oil:gas solubility coefficient (37°C) 224 91 47 
Ether linkage No Yes Yes 
Preservative Yes No No 
Halogen Br, Cl, F Cl, F F 
Molecular weight (g) 197.4 184.49 200.05 
Liquid specific gravity (g/ml) 1.86 1.49 1.52 
 
Table 1.1: Selected, relevant chemical data for halothane, isoflurane and 
sevoflurane 
Br: Bromine 
Cl: Chlorine 
F: Fluorine 
 
1.1.3 Method of action 
Surprisingly little is known about the methods or sites of action of inhaled 
anaesthetic agents. This is coupled with a difficulty in even defining the term 
anaesthesia (Eger et al. 2002). Whilst many elements may be said to constitute the 
state of anaesthesia, it has been hypothesised that the fundamental constituents of 
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anaesthesia are immobility and amnesia – the surgeon wants an immobile patient, the 
patient wants not to remember the surgeon’s attentions (Eger et al. 2002). Other 
elements such as muscle relaxation and suppression of autonomic reflexes are often 
but not always associated with this state. 
It appears likely that immobility is mediated through action by the volatile 
agent on the spinal cord, possibly due to effects on motor neurons (Rampil and King 
1996). Decerebration, or even transection of the spinal cord from the brain, does not 
decrease the anaesthetic dose required to prevent movement in response to stimulus 
(Rampil et al. 1993). 
Amnesia is more likely the result of effects somewhere in the higher centres, 
potentially the reticular formation, amygdala, hippocampus, or cerebral cortex 
(Koblin 1994; Eger et al. 2002). 
 
1.1.4 Therapeutic effects 
1.1.4.1 Dose requirements 
Dose requirements for general anaesthesia by inhalant agents are compared by 
determination of Minimum Alveolar Concentration (MAC). The MAC is defined as 
the minimum end-expiration anaesthetic concentration sufficient to suppress 
conscious response in 50% of patients exposed to a standard noxious stimulus, often 
clamping of an extremity or a mild electric shock (Eger et al. 1965). Calculated 
halothane, isoflurane and sevoflurane MAC values for dogs are presented in Table 
1.2. A dose sufficient to produce immobility in 95% of patients (ED95) has been 
calculated in humans to be 1.2 to 1.4.MAC. Dose requirements for normal surgery 
may be expected to be similar (Steffey 1996). The MAC will be varied by the use of 
concurrent medications such as sedatives and intravenous induction agents. It will 
also be modified by other circumstances such as body temperature, age, variations in 
blood pressure and systemic disease. The dose requirement is inversely proportional 
to the agent’s oil:gas solubility (Table 1.1), representing the affinity of that agent for 
lipids, such as the membranes of neuronal tissue.  
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 Canine MAC (%) References 
Halothane 0.86-0.93 
Merkel and Eger 
1963 
 
Isoflurane 1.28-1.30 
Steffey and 
Howland 1977; 
Steffey, Baggot et 
al. 1994 
 
Sevoflurane 2.09-2.35 
Mutoh, Nishimura 
et al. 1997; 
Kazama and Ikeda 
1988 
 
  
Table 1.2: Canine dose requirements for inhalant anaesthetics 
 
 
1.1.4.2 Factors affecting induction of anaesthesia 
Halothane, isoflurane and sevoflurane have been used for the induction of 
general anaesthesia by mask inhalation. The speed and quality of mask induction is 
dependent upon factors related to the patient and to the agent.  
From the point of view of the agent, the most important factors related to 
induction of anaesthesia are its blood:gas solubility and irritancy to the respiratory 
tract. A lower blood:gas solubility implies that less of the agent must be absorbed 
before concentrations will begin to rise in the target tissues, primarily the central 
nervous system (Dale and Brown 1987; Steffey 1996). As shown in Table 1.1, 
sevoflurane is considerably less soluble in blood than isoflurane, which in turn is less 
soluble than halothane. Sevoflurane’s advantage over isoflurane in this area is 
accentuated by sevoflurane’s more “pleasant” odour, which improves pulmonary 
ventilation during induction and is further discussed below (Section 1.1.5.3.1).  
The most important patient factors influencing the speed of inhalant agent 
induction of anaesthesia are cardiac output, alveolar ventilation, and the concentration 
gradient between pulmonary arterial blood and alveolar gas (Eger 1974). As cardiac 
output increases, a greater volume of blood will pass through the lungs and thus 
increase the quantity of inhaled agent absorbed from the alveolar gas, decreasing the 
time required to saturate the blood volume with the agent. Improving alveolar 
ventilation, the volume of gas inspired and expired by the animal over a given period, 
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will obviously increase the quantity of agent available to be absorbed by the 
pulmonary blood flow. The movement of molecules of the inhalant agent from 
alveolar gas to pulmonary blood is a passive process, and thus will be most rapid in 
the presence of a strong concentration gradient between the two. In practical terms, 
this means the swiftest changes in agent concentrations in the central nervous system 
will be produced by the use of the highest feasible inhaled concentrations. These 
factors interplay with those related to the agent. Alveolar ventilation, for instance, will 
be markedly affected by the animal’s acceptance of the mask or other means of agent 
administration, and by the pungency or irritancy of the agent.  
The influence of these factors may be expressed in the following equation 
(Eger 1994): 
 
Uptake =  . Q . (PA  -  PV) / BP 
 
  =  Blood:gas solubility of agent 
Q =  Cardiac Output 
PA =  Alveolar partial pressure of agent 
PV =  Pulmonary venous partial pressure of agent 
BP =  Barometric pressure 
 
Two experimental studies have compared induction speed and quality using 
equipotent doses of inhalant agents in the dog. A comparison of isoflurane to 
sevoflurane for induction of unpremedicated dogs showed sevoflurane induction to be 
significantly faster and of better quality, taking a mean of 5.7min to endotracheal 
intubation, compared to 8.6min for isoflurane (Johnson et al. 1998). A maximum dose 
of 2.0.MAC was used for each agent, achieved in several steps over an initial 45sec. 
Inhalation of 2.5.MAC of halothane, isoflurane and sevoflurane allowed endotracheal 
intubation in a mean of 13.12, 4.76 and 3.48min respectively (Mutoh et al. 1995). 
Sevoflurane induction was associated with significantly fewer “movements” during 
mask inhalation than the other two agents, although this term was not further defined. 
A study described only in abstract form also demonstrated faster induction of 
anaesthesia with sevoflurane in comparison to isoflurane when equipotent doses of 
2.5.MAC were used in premedicated dogs (Cantalapiedra et al. 1999). These results 
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correlate relatively closely with summaries of data from human studies (Patel and Goa 
1996).  
Vaporiser settings of 2.5.MAC, being at most 2.3, 3.3 and 5.9% for halothane, 
isoflurane and sevoflurane respectively, are well below the maximum settings 
available on a standard precision vaporiser such as a Tec 3 (Cyprane, Keighley, 
England). The maximum inhalant concentrations available on vaporisers for these 
agents is 5.0, 5.0, and 8.0% respectively. Therefore, these vaporisers allow for 
maximum delivered concentrations of at least 5.4, 3.8 and 3.4.MAC for the three 
agents. Using these higher concentrations for inhalant induction is common practice 
in human and veterinary anaesthesia (Patel and Goa 1996; Agnor, Sikich et al. 1998; 
Haitjema and Cullen 2001; C.Dart, pers. comm.). One experimental study compared 
halothane and isoflurane for induction of anaesthesia in the dog using a vaporiser 
setting of 4.5%, achieved by increasing vaporiser setting by 0.5% every 60sec 
(Hellebrekers 1986). This equates to approximately 4.8.MAC and 3.5.MAC for 
halothane and isoflurane respectively. Using this protocol, no significant difference 
was seen between the two agents in terms of time to intubation, which was achieved 
in 7.1 to 7.5min in both groups.  
A small number of studies have investigated the speed of induction of 
anaesthesia using roughly equipotent doses of isoflurane or sevoflurane in the cat. In 
clinical patients undergoing desexing, induction by mask with sevoflurane was 
significantly faster (210 ± 57sec, mean ± SD) than induction by isoflurane (264 ± 
75sec)(Lerche et al. 2002). An earlier study described satisfactory induction of 
anaesthesia in cats with 8% sevoflurane in 33% oxygen, 66% nitrous oxide, the cats 
usually able to be placed in lateral recumbency within 1min (Tzannes et al. 2000).  
Two studies have investigated speed of induction in cats placed in induction 
chambers. One study showed significantly shorter time to intubation using 2.7.MAC 
doses of sevoflurane in comparison to isoflurane (434 ± 66sec vs 515 ± 69sec)(Imai et 
al. 2003). However, a similar study using 5% isoflurane and 8% sevoflurane showed 
no significant difference in time to intubation (Ko et al. 2001).  
Two studies have evaluated whether human anaesthetists were able to reliably 
discern whether they were using halothane or sevoflurane to mask induce children, the 
agent being randomly allocated and vaporiser hidden from view. In one study, only 
the staff anaesthetists and not the anaesthesia residents were able to discern the agent 
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used (Morimoto et al. 2000). The group of anaesthetists in the second study were not 
able to reliably discern the agent used (Bacher et al. 1997).  
In a multisite case series report comparing quality of induction of anaesthesia 
using sevoflurane with other standard anaesthesia protocols, no significant differences 
were found between groups (Branson et al. 2001). However, this study was limited by 
variation in the protocols employed for premedication and induction, with a large 
number of operators involved, potentially decreasing the ability to detect differences 
between the groups.  
 
1.1.4.3 Recovery from anaesthesia 
Summaries of data from humans indicate more rapid recovery from 
anaesthesia induced and maintained with sevoflurane than with halothane in children, 
based on time to extubation and psychomotor testing (Patel and Goa 1996). Likewise, 
recovery from sevoflurane anaesthesia in adult humans is generally faster than that 
from isoflurane anaesthesia (Patel and Goa 1996). 
In unpremedicated dogs mask induced with isoflurane or sevoflurane, no 
significant differences could be found in any recovery variable, with extubation in a 
mean of 5.9 and 6.4min respectively, and most recoveries rated as “excellent” 
(Johnson et al. 1998). Neither could significant differences be found between 
recoveries in dogs anaesthetised using halothane, isoflurane or sevoflurane after 
induction with propofol (Polis et al. 2001).  
 
 1.1.5 Side effect profile 
1.1.5.1 Effects on cerebral function 
The effect of halogenated anaesthetics, measured in terms of EEG function, is 
somewhat two-pronged. Generally, a dose-dependent depression and slowing of 
activity is seen, progressing to isoelectricity (Modica et al. 1990). However, many of 
the volatile anaesthetics, and particularly those containing an ether linkage, are also 
associated with proconvulsant properties (Modica et al. 1990).  
Halothane alone has not been reported to cause seizures in humans or dogs, 
although there are sporadic reports of seizure activity in humans when it is 
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administered with nitrous oxide (Modica et al. 1990; Steffey 1995). Isoflurane has not 
been reported to induce EEG evidence of seizure at any level of anaesthesia, either in 
human or dog (Scheller et al. 1990; Rampil et al. 1991).  
There are no reports of seizures in dogs associated with sevoflurane. Healthy 
dogs anaesthetised with up to 2.5.MAC sevoflurane showed no EEG evidence of 
seizure, when exposed to hypocapnia and/or intense auditory stimuli (Scheller et al. 
1990). However, two of 13 cats anaesthetised with this agent showed EEG evidence 
of seizure activity, provoked by electrical stimulation (Osawa et al. 1994). There are 
several case reports of seizures in non-epileptic and epileptic humans associated with 
sevoflurane anaesthesia (Adachi et al. 1992; Terasako and Ishii 1996; Woodforth et 
al. 1997; Kaisti et al. 1999; Iijima et al. 2000). Mask induction of non-epileptic 
humans with sevoflurane in a mixture of O2 and N2O revealed EEG evidence of 
seizure activity, with a heart rate increase of at least 30% being consistently 
associated with the seizure activity (Yli-Hankala et al. 1999). It may be questioned as 
to what electrical activity may be occurring in the canine brain during mask induction 
with sevoflurane, given the heart rate increases that are often recorded (Section 
1.1.5.2.1). Unfortunately, these responses have not been studied in detail. 
 
1.1.5.2 Effects on the cardiovascular system 
1.1.5.2.1 Effects on heart rate 
Mask induction of general anaesthesia in dogs using isoflurane or sevoflurane 
causes significant elevations in heart rate from baseline values (Mutoh et al. 1995). In 
contrast, inductions with halothane are not accompanied by significant changes in 
heart rate. These patterns persist throughout the maintenance phase of anaesthesia 
with the respective agents (Harkin et al. 1994; Mutoh et al. 1995; Mutoh et al. 1997; 
Polis et al. 2001), the elevations with isoflurane and sevoflurane being in the order of 
30-40% with expired agent concentrations equivalent to 1.0.MAC to 2.0.MAC. 
However, one study showed decreases in heart rate with inspired concentrations of up 
to 3% sevoflurane (Yamada et al. 1994).  
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1.1.5.2.2 Effects on cardiac rhythm 
Halothane’s predilection for lowering the threshold to catecholamine-induced 
cardiac arrhythmias was one of the major motivations for further development of 
inhalant anaesthetics (Wallin et al. 1975; Steffey 1995). The plasma adrenaline 
(epinephrine) concentrations required to produce arrhythmias were established to be 
39.1, 149.2, and 275.7ng.ml-1 for halothane, isoflurane and sevoflurane respectively 
(Imamura and Ikeda 1987). The use of thiobarbituates for induction of anaesthesia 
lowers the arrhythmogenic threshold concentration (Atlee and Malkinson 1982; 
Hayashi et al. 1988). Arrhythmogenic concentrations of adrenaline for the latter two 
agents result in marked hypertension (Imamura and Ikeda 1987; Hayashi et al. 1988).  
 
1.1.5.2.3 Effects on cardiac contractility 
Halothane, isoflurane and sevoflurane are all associated with depression of 
most measurable indicators of cardiac contractility in the dog (Bernard et al. 1990; 
Harkin et al. 1994; Mutoh et al. 1995; Mutoh et al. 1997). These agents cause a 
decrease in the concentration of free Ca2+ available within the myocardial cells 
(Bosnjak et al. 1988), reducing the strength of contraction of which the cell is capable. 
This decrease in Ca2+ concentration is due to slowing of the influx of Ca2+ through the 
sarcolemma (Bosnjak et al. 1988), decreases in Ca2+ accumulation in the sarcoplasmic 
reticulum (Su and Kerrick 1979), and decreases in contractile protein sensitivity to 
Ca2+ (Su and Bell 1986).  
The depression of three important cardiac variables was almost identical 
during 2.MAC isoflurane or sevoflurane anaesthesia in dogs (Bernard et al. 1990). 
Cardiac output decreased by 17 ± 6% (mean ± SE), stroke volume decreased by 48 ± 
4%, and left ventricular rate of pressure change (dP/dt) dropped by 61 ± 10%. Cardiac 
output and stroke volume were lower in dogs anaesthetised with 2.0.MAC halothane 
than in dogs anaesthetised with the equivalent level of isoflurane (Steffey and 
Howland 1978). However, no significant differences in cardiac index or stroke index 
were found in dogs anaesthetised with halothane, isoflurane or sevoflurane in a more 
recent study (Mutoh et al. 1997). Echocardiographic measurements during mask 
induction of anaesthesia with halothane or sevoflurane in children revealed 
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significantly less depression of left ventricular shortening fraction and velocity of 
circumferential fibre shortening with sevoflurane (Holzman et al. 1996).  
 
1.1.5.2.4 Effects on diastolic function 
Although most studies of cardiac performance focus on systolic variables, 
diastolic performance should not be ignored (Plotnick 1989; Grossman 1990). In 
contrast to halothane, anaesthesia with isoflurane or sevoflurane does not affect 
ventricular relaxation or chamber stiffness (Yamada et al. 1994), producing an 
improved preload with the newer agents.  
 
1.1.5.2.5 Effects on vasculature 
1.1.5.2.5.1 Systemic vasculature 
Halothane, isoflurane and sevoflurane all cause systemic vasodilation at 
anaesthetic doses (Bernard et al. 1990; Malan et al. 1995; Mutoh et al. 1995; 
Holzman et al. 1996; Mutoh et al. 1997). Isoflurane and sevoflurane produce a similar 
degree of vasodilation (Bernard et al. 1990; Malan et al. 1995; Mutoh et al. 1995; 
Mutoh et al. 1997), generally greater than that produced by halothane (Pagel et al. 
1991; Holzman et al. 1996), although results of some studies do not concur (Mutoh et 
al. 1995; Mutoh et al. 1997).  
 
1.1.5.2.5.2 Coronary vasculature 
Coronary vasculature is also dilated by these agents (Bernard et al. 1990; 
Harkin et al. 1994; Hirano et al. 1995). Sevoflurane may prevent the induction of 
“coronary steal” which has been controversially attributed to isoflurane, by better 
regulation of coronary arteriolar diameter (Mayer et al. 1991). “Coronary steal” refers 
to the preferential perfusion of normal areas of myocardium at the expense of those 
with stenosed vasculature, occurring after administration of a coronary vasodilator. It 
has only been recorded in the dog in the experimental setting (Blanck and Lee 1994). 
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1.1.5.2.5.3 Cerebral vasculature 
In suppressing cerebral neuronal activity, volatile anaesthetics induce a dose-
dependent decrease in the cerebral metabolic requirement for oxygen (CMRO2) of 
about 30% in the case of isoflurane and sevoflurane (Scheller et al. 1990). 
Vasodilation of the cerebral vessels caused by halothane leads to increased cerebral 
blood flow (CBF) and intracranial pressure (ICP) (Steffey 1995; Patel and Goa 1996; 
Eger et al. 2002). Increased ICP may be deleterious to animals with intracranial 
pathology. In contrast, isoflurane and sevoflurane may retain these values within 
normal ranges (Scheller et al. 1990; Kuroda et al. 1997; Monkhoff et al. 2001). CBF 
is normally tightly regulated by homeostatic mechanisms and coupled to CMRO2. 
This regulation is probably retained with 1.5.MAC isoflurane and sevoflurane 
anaesthesia (Kuroda et al. 1997). 
 
1.1.5.2.6 Effects on blood pressure 
Arterial blood pressure is a product of systemic vascular resistance and cardiac 
output (Ebert et al. 1995). Although mean arterial pressure (MAP) is generally higher 
with halothane than with equipotent doses of isoflurane or sevoflurane in humans, 
dogs or horses, establishing significant differences has been difficult given the small 
groups involved in most studies (Bernard et al. 1990; Frink et al. 1992a; Murray et al. 
1992; Harkin et al. 1994; Malan et al. 1995; Mutoh et al. 1995; Holzman et al. 1996; 
Mutoh et al. 1997; Grosenbaugh and Muir 1998). A decrease in MAP of 
approximately 20% at 1.5.MAC is routinely found for each of the agents. Sevoflurane 
and isoflurane realise lower MAP values due to their greater vasodilation relative to 
halothane (Section 1.1.5.2.5).  
In human patients, MAP following induction with propofol and maintenance 
with sevoflurane was lower than that following induction by mask with sevoflurane 
(Smith et al. 1992). 
 
1.1.5.3 Effects on the Respiratory System 
1.1.5.3.1 Odour and Irritancy 
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Halothane is described as having a “sweet” or “pleasant” odour (Dale and 
Brown 1987; Quail 1989). Sevoflurane is likewise endowed with a “pleasant” smell 
(Wallin et al. 1975; Patel and Goa 1996). The smell of isoflurane, on the other hand, 
is described as “pungent, ethereal” (Quail 1989), or “unpleasant” (Dale and Brown 
1987).  
The pungency of isoflurane often ruled out its use for mask induction in 
children, and halothane was used for this purpose until the introduction of sevoflurane 
(Agnor et al. 1998; Feiss 2000). A study in humans showed sevoflurane to have the 
least effect on respiratory system function during mask inhalation, causing no 
coughing or change in respiratory rate or functional residual capacity (Doi and Ikeda 
1993). Halothane was the second least irritant agent, whilst isoflurane was the most 
irritant.  
Administration of inhalants to the upper airways of dogs intubated via 
tracheotomy showed significant decreases in respiratory rate, tidal volume and minute 
ventilation with isoflurane, whilst there were no significant changes with sevoflurane 
(Mutoh et al. 2001). These isoflurane-related changes were ablated by nebulisation of 
lignocaine, supporting the suggestion that upper airway irritation is an important 
mediator of the respiratory system changes recorded during induction with isoflurane.  
 
1.1.5.3.2 Respiratory effects post-induction 
Halothane is the least respiratory depressant of the three inhalant agents in the 
dog (Mutoh et al. 1995; Steffey 1996; Mutoh et al. 1997). All three cause a decrease 
in ventilation, measured in terms of minute expired ventilation and arterial CO2 
(Mutoh et al. 1995; Mutoh et al. 1997). Isoflurane and sevoflurane showed a similar 
degree of respiratory depression, though only sevoflurane was significantly worse 
than halothane (Mutoh et al. 1997). Nevertheless, increases of arterial CO2 to 
approximately 45mmHg at doses equal to 1.5.MAC indicate only a moderate degree 
of respiratory depression even with the two newer agents. 
Halothane is significantly more effective at inhibiting bronchoconstriction 
following antigen or histamine challenge in the dog when compared to either 
isoflurane or sevoflurane (Yamakage et al. 1993). 
Hypoxic pulmonary vasoconstriction occurs in the normal animal to divert 
pulmonary blood flow away from areas of unventilated lung to maximise gas 
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exchange. In vitro, inhalant anaesthetics blunt this response, in line with their 
generalised vasodilatory effects (Ishibe et al. 1993). However, this seems not to be 
clinically significant at normal doses in vivo, with the response to hypoxia preserved 
(Okutomi and Ikeda 1990; Eger et al. 2002). 
 
1.1.5.4 Effects on renal function 
In rats, halothane has been shown to produce a decrease in renal blood flow; 
the percentage of cardiac output perfusing the kidneys in unchanged (Crawford et al. 
1992). Sevoflurane produced no change in renal blood flow in this study. However, in 
the dog, halothane and isoflurane produced no change in flow to the renal cortex 
(Gelman et al. 1984). 
Degradation of inhaled anaesthetics releasing inorganic fluoride has potential 
for nephrotoxicity (Mazze et al. 1971). Quantities of fluoride produced during 
halothane and isoflurane anaesthesia do not approach toxic concentrations (Fee and 
Thompson 1997). Sevoflurane, however, is notably metabolised in the liver to 
produce inorganic fluoride at concentrations which may approach or even exceed the 
suggested toxic threshold for humans of 50µM in plasma (Kazama and Ikeda 1991; 
Kobayashi et al. 1992; Frink et al. 1994; Eger et al. 1997a; Eger et al. 1997b). Such 
plasma fluoride concentrations produced high output renal failure in humans (Mazze 
et al. 1971; Cousins and Mazze 1973) and rats (Cousins et al. 1974) following 
anaesthesia with the older inhalant agent methoxyflurane. However, despite the 
application of an enormous research effort, no evidence of postoperative renal 
compromise in terms of renal concentrating ability or blood urea concentrations has 
been found after sevoflurane anaesthesia (Higuchi et al. 1995; Bito et al. 1997; Eger 
et al. 1997a; Eger et al. 1997b; Kharasch et al. 1997; Ebert et al. 1998; Higuchi et al. 
1998; Nishiyama and Hanaoka 1998; Mazze et al. 2000; Goeters et al. 2001). This 
may be due to the fact that sevoflurane degradation primarily occurs in the liver 
whereas methoxyflurane degradation occurs in the kidneys themselves (Kharasch et 
al. 1995).   
Furthermore, sevoflurane degrades in strongly basic environments to produce 
several compounds, for simplicity labelled Compounds A-E (Patel and Goa 1996). 
Compound A, a vinyl ether, is the most important of these, produced when 
sevoflurane interacts with common carbon dioxide absorbents (Cunningham et al. 
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1996). Inspired concentrations of Compound A of greater than 50ppm were 
nephrotoxic to rats (Keller et al. 1995). These concentrations may be produced during 
human anaesthesia with sevoflurane, particularly when high sevoflurane 
concentrations and low fresh gas flow rates are used (Eger et al. 1997a; Eger et al. 
1997b; Kharasch et al. 1997; Goeters et al. 2001). However, as mentioned previously, 
no evidence of decreased renal concentrating ability or increased blood concentrations 
of urea or creatinine have been noted following sevoflurane anaesthesia. This may be 
due to a lower activity in the human kidney of the enzyme -lyase, which converts 
Compound A to more toxic metabolites in the rat kidney (Keller et al. 1995; Patel and 
Goa 1996).  
There have been no reports relating to the effects of degradation of 
sevoflurane in dogs. 
 
1.1.5.5 Effects on the liver 
Blood and oxygen flow to the liver is decreased with anaesthetic doses of 
halothane (Frink et al. 1992b), the reductions being marked at 1.5 and 2.0.MAC. Both 
hepatic arterial flow and portal vein flow is reduced with this agent. Isoflurane and 
sevoflurane are associated with maintenance of hepatic arterial blood flow to at least 
1.5.MAC (Bernard et al. 1992; Frink et al. 1992b), although portal vein flows 
decrease. However, the reductions reported with halothane are not considered to have 
clinical consequences in the absence of complicating factors such as hypoxaemia or 
systemic disease (Steffey 1995). 
Halothane, isoflurane and sevoflurane all undergo biotransformation in vivo, 
primarily in the liver (Fee and Thompson 1997). Approximately 20-25% of inspired 
halothane is recovered as metabolites, whereas only 0.17% and 3% of isoflurane and 
sevoflurane respectively are biotransformed (Steffey 1995).  
Halothane has been widely reported to cause hepatic injury in people (Ray and 
Drummond 1991; Fee and Thompson 1997; Eger et al. 2002). The most severe form 
is a fulminant hepatitis with high mortality, reported most commonly after repeated 
administrations (Ray and Drummond 1991). The aetiology of this syndrome (or 
syndromes) probably includes metabolic and immunological effects (Fee and 
Thompson 1997). There is a case report of similar pathology following halothane 
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anaesthesia in a series of goats (O'Brien et al. 1986). This syndrome has not been 
reported in the dog. 
Isoflurane and sevoflurane have both been linked to hepatotoxicity in humans, 
although, in line with their greater biostability, the prevalence is far lower (Sinha et al. 
1996; Turner et al. 2000; Bruun et al. 2001). As discussed above (Section 1.1.5.4), 
sevoflurane degradation releases inorganic fluoride ion, although this seems not to be 
of clinical significance. There are no case reports of isoflurane or sevoflurane 
hepatotoxicity in animals.  
 
1.1.6 Hazards of occupational exposure 
Similar to its hepatic effects in patients, halothane may cause decreased 
hepatic function in staff members exposed to the agent incidentally (Byhahn et al. 
2001). Isoflurane and sevoflurane are not thought to cause hepatic pathology in those 
chronically exposed to low concentrations.  
Halothane has been shown to be teratogenic in rats, mice and hares exposed to 
conditions similar to a poorly ventilated operating theatre (Byhahn et al. 2001). Mask 
inductions markedly increase the concentrations present in the theatre atmosphere, 
which may exceed recommend legislated limits (Hoerauf et al. 1997; Hoerauf et al. 
1999). Minimal examination of the teratogenicity of isoflurane has been undertaken, 
and none for sevoflurane. No similar studies have been performed in the clinical 
veterinary environment. 
 
1.1.7 Environmental effects 
As halogenated compounds, halothane, isoflurane and sevoflurane have the 
potential to contribute to breakdown of the stratospheric ozone layer and “greenhouse 
effect”. Normal practice in veterinary and human anaesthesia is to vent these inhalant 
anaesthetics to the atmosphere without modification. Global production of these 
agents has been estimated at 10kilotons per year (Langbein et al. 1999). Laboratory 
analysis and computer modelling suggests halothane has an ODP (Ozone Depletion 
Potential) of 1.56, with CFC-11 as a reference value of 1.00. The ODP for isoflurane 
and sevoflurane is 0.03 and 0.00 respectively (Langbein et al. 1999). Halothane’s high 
value is due to its bromine content, whilst sevoflurane evades ozone depletion due to 
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its lack of either bromine or chlorine. Values for GWP (Greenhouse Warming 
Potential) suggested for halothane, isoflurane and sevoflurane are 0.02, 0.05 and 0.02, 
where CFC-12 is the reference of 1.00 (Langbein et al. 1999). These calculations led 
to the approximation that 0.03% of global warming is likely due to halogenated 
anaesthetics. The impact of these agents will decrease as halothane use in human 
anaesthesia decreases.  
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1.2 Propofol 
 
1.2.1 Composition 
Propofol is an intravenous anaesthetic agent, a derivative of phenol, 
chemically described as 2,6-diisopropylphenol. It was first synthesised in the early 
1970’s. It is insoluble in water. Initially, it was solubilised in Cremophor EL, but the 
high incidence of anaphylactoid reactions associated with this solvent led to its 
reformulation in an emulsion containing soybean oil, glycerol, egg lecithin and 
sodium hydroxide (Reves et al. 1994; Branson 2001). This emulsion contains no 
preservative, and will support bacterial and fungal growth (Bryson et al. 1995). 
Concern over outbreaks of infection traceable to contaminated propofol led to one 
manufacturer adding EDTA to the emulsion, which seems to have been effective in 
halting such outbreaks (Shafer 2002).  
 
1.2.2 Pharmacokinetics 
The pharmacokinetics of propofol in dogs best fits a two compartment open 
model (Zoran et al. 1993). Distribution to the CNS is rapid, followed by a slower 
elimination that relies heavily on metabolism. However, redistribution to tissues such 
as muscle probably accounts for most of the decrease in plasma concentration 
required for termination of propofol’s hypnotic effects (Zoran et al. 1993). In mixed-
breed dogs given a single induction bolus of propofol for endotracheal intubation, 
recovery to sternal recumbency and to standing occurred at plasma propofol 
concentrations of 0.753 ± 0.484 and 0.676 ± 0.338g.ml-1 respectively. Mean plasma 
concentrations at 60min post-induction were 0.161 ± 0.059g.ml-1 in mixed breed 
dogs (Zoran et al. 1993), indicating a concentration well below that expected to 
influence recovery if anaesthesia was maintained with a gaseous agent. In this study, 
greyhounds showed notably slower recoveries, with higher peak plasma propofol 
concentrations and recovery occurring at higher plasma concentrations. This is likely 
due to differing body composition, and a lower capacity for hepatic metabolism.  
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1.2.3 Metabolism 
Hepatic metabolism is undoubtedly significant in propofol-anaesthetised 
patients, but other sites are involved (Zoran et al. 1993). Humans undergoing hepatic 
transplant were able to metabolise propofol to a similar degree when no liver blood 
flow was present (Veroli et al. 1992). Metabolites are primarily excreted in the urine 
(Bryson et al. 1995). 
 
1.2.4 Induction of and recovery from anaesthesia 
Propofol induces general anaesthesia when administered by intravenous 
injection, generally as a single bolus. Early described doses to allow endotracheal 
intubation in unpremedicated dogs ranged from 5.2 ± 2.6mg.kg-1 (Weaver and 
Raptopoulos 1990) to 6.55 ± 1.7mg.kg-1 (Morgan and Legge 1989). Premedication 
with various agents, most commonly acepromazine, lowered these doses to 3.6 ± 1.4 
and 4.5 ± 1.53 mg.kg-1 respectively. Apnoea of up to 30sec duration has been noted 
commonly upon induction (Watkins et al. 1987; Morgan and Legge 1989; Short and 
Bufalari 1999). Slowing the rate of administration appears to decrease the incidence 
of this complication (Watkins et al. 1987). Induction is generally quiet, smooth and 
excitement-free (Watkins et al. 1987). Lower doses of propofol for endotracheal 
intubation may in turn require supplementary boluses if anaesthesia is to be 
maintained using inhalants, due to the rapid clearance of propofol (Weaver and 
Raptopoulos 1990). 
Recovery after a single induction bolus of propofol was judged complete in 18 
± 7min in unpremedicated dogs, and 22 ± 10min in dogs premedicated with low doses 
of acepromazine (Watkins et al. 1987). Mixed breed, unpremedicated dogs stood after 
14.63 ± 3.6min in another study, whereas greyhounds took 21.7 ± 3.3min (Zoran et al. 
1993). Recovery after a two hour continuous infusion of propofol was similar to an 
equivalent period of isoflurane anaesthesia, with extubation in a mean of 13.5min, 
compared to 12.7min after isoflurane (Keegan and Greene 1993). 
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1.2.5 Side effects profile 
1.2.5.1 Cardiovascular effects 
Mild elevations in heart rate are commonly reported during induction of 
anaesthesia with propofol, however these do not reach statistical significance in most 
studies (Hall and Chambers 1987; Ilkiw et al. 1992; Bufalari et al. 1997). A drop over 
time may occur in dogs maintained by constant infusion of propofol (Hall and 
Chambers 1987; Keegan and Greene 1993). The presence of a stable heart rate despite 
a significant drop in arterial blood pressure was theorised to be due to a resetting of 
the baroreceptor reflex (Cullen et al. 1987), although more recently direct depression 
of baroreceptor response by propofol has been demonstrated (Sellgren et al. 1994). 
Induction doses of propofol in the dog are associated with a decrease in 
cardiac output that approaches 20% one minute after administration. Propofol has 
direct effects on myocardial contractility, decreasing maximum left ventricular force 
by 15-20% (Brussel et al. 1989; Pagel and Warltier 1993). A similar degree of 
depression of systolic and diastolic blood pressure is reported (Brussel et al. 1989). A 
simultaneous decrease in systemic vascular resistance of 11.6% occurs, predominantly 
due to effects on arteries and arterioles rather than capacitance vessels.  Moderate 
hypovolaemia does not change the degree of these effects (Ilkiw et al. 1992). These 
variables rebound close to baseline values by five minutes after administration 
(Brussel et al. 1989; Ilkiw et al. 1992).  
 
1.2.5.2 Respiratory effects 
Apnoea upon administration is a common side-effect noted with propofol 
(Watkins et al. 1987; Morgan and Legge 1989; Keegan and Greene 1993; Zoran et al. 
1993; Short and Bufalari 1999). This is noted to be transitory in nature, undoubtedly 
linked to the rapid clearance of propofol. Injection over up to 40sec., and giving to 
effect rather than a predetermined dose, minimise this effect (Watkins et al. 1987).  
Commensurate with this often reported complication on induction is 
respiratory depression throughout the period of anaesthesia. Arterial CO2 is increased, 
although whilst this increase is statistically significant, it may not be biologically 
significant, with a rise to 41.9mmHg from 34.6mmHg five mintues after induction in 
one study of mixed breed dogs (Robertson et al. 1992). Respiratory rate decreases 
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moderately (Robertson et al. 1992). The respiratory effects of a continuous infusion of 
propofol for general anaesthesia are similar in magnitude to isoflurane anaesthesia 
(Keegan and Greene 1993).  
 
1.2.5.3 Proconvulsant/anticonvulsant effects 
Propofol has been associated with seizure activity in humans. This includes 
whole-body tonic-clonic seizure activity and abnormal movements (Makela et al. 
1993; Borgeat 1997). These are most commonly, though not exclusively associated 
with induction of anaesthesia. These are more commonly seen in patients with pre-
existing epilepsy (Makela et al. 1993; Bryson et al. 1995). However, there is a 
suggestion that these events are subcortical in origin, and therefore should not be 
considered epileptic (Borgeat 1997). Involuntary movements, trembling or even mild 
tonic-clonic activity are noted to occasionally occur during or after induction of 
anaesthesia with propofol in dogs, and may last for the duration of anaesthesia 
(Weaver and Raptopoulos 1990; Robertson et al. 1992; Zoran et al. 1993). No studies 
of the canine electroencephalogram during these complications have been undertaken. 
None of the reports of such activity in dogs note any postoperative neurologic deficits 
in these animals. 
Propofol has also been shown to have anticonvulsant properties. It has been 
successfully used to treat seizures of intracranial origin and following portosystemic 
shunt surgery in dogs (Heldmann et al. 1999; Steffen and Grasmueck 2000). The 
doses required may be so low as to allow the animal to eat and drink whilst on a 
constant rate infusion of propofol. Status epilepticus in the human has also been 
treated with propofol (Borgeat 1997). 
The exact means of action for these effects of propofol is unknown. Unlike 
thiobarbituates, in which antiepileptic action is mainly mediated by the GABA 
receptor, propofol causes a more uniform depression of CNS activity (Borgeat 1997). 
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1.3 Acepromazine 
1.3.1 Introduction 
 Acepromazine (ACP) is a derivative of the compound phenothiazine, 
chemically described as 2-acetyl-10-(3-dimethylaminopropyl) phenothiazine. Its 
tranquillising properties make it a common choice of premedicant for anaesthesia in 
the dog. It has been in veterinary use since the early 1960’s. Phenothiazine derivatives 
are classed as neuroleptics due to both their tranquillising effects and their ability to 
modify psychotic behaviours in humans  (Gross 2001). 
 
1.3.2 Method of action 
Phenothiazine and its derivatives act primarily through blocking dopamine in 
the central nervous system (CNS), and the effects of dopamine and other 
catecholamines in the periphery. Following administration, the rate of dopamine 
turnover in the brain is increased (Hornykiewicz 1973; Matthysse 1973). Brain stem 
activity is depressed, as are the connections to the cerebral cortex (Pugh 1964; Gross 
2001).   
In the periphery, catecholamine function, most specifically -adrenergic 
function, is blocked by ACP and other phenothiazines. This property elicits most of 
the cardiovascular side-effects of ACP.  
 
1.3.3 Therapeutic effects 
Although the term sedation is sometimes used to describe the effects of ACP, 
tranquillisation is perhaps more accurate. Tranquillisation refers to “a state of 
sedation not accompanied by the lethargy and apathy associated with most sedatives. 
Tranquillisation proper need not be objectively detectable, because the motor cortex 
need not be markedly depressed” (Pugh 1964).  
Published intramuscular doses used for producing tranquillisation in dogs vary 
from 0.04mg/kg (Rutherford 1983) to 1.0mg/kg (Popovic et al. 1972). Lower doses 
have gained popularity in more recent times, particularly in combination with other 
drugs. Rutherford (1983) coined an often repeated suggestion to use no more than 
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3.0mg total dose per dog, and even lower doses in large dogs, although the basis for 
this recommendation was not elucidated. The effects produced include changes to the 
skin of the face, with looser, wrinkled skin over the frontal bones, drooping of the 
upper eyelid and protrusion of the nictitating membrane (Pugh 1964). “Voluntary” 
recumbency follows signs of posterior in-coordination. Dogs become more amenable 
to handling. These effects appear to abate after about 3-4hr (Pugh 1964). 
The use of ACP alone decreases anaesthetic requirements both for induction 
with agents such as thiopentone (Pugh 1964; Raiha et al. 1989) and inhalants such as 
halothane (Raiha et al. 1989), with a 0.04mg/kg IM dose decreasing the halothane 
MAC by 46% (Heard et al. 1986).  
ACP also acts as an anti-emetic (Valverde et al. 2003), and is effective in 
raising the threshold for catecholamine-induced ventricular fibrillation in dogs 
anaesthetised with thiamylal and halothane (Muir et al. 1975).  
Most studies of the effects of ACP have used it in combination with various 
opioids, a combination known as neuroleptanalgesia (Gross 2001). Such opioids 
include oxymorphone and butorphanol. As well as adding analgesia, which is 
effectively absent with ACP alone (Barnhart et al. 2000a), these combinations show 
longer duration of action and should decrease the dose requirement of ACP (Barnhart 
et al. 2000a).   
 
1.3.4 Side effects profile 
Due primarily to its -adrenergic antagonist action, ACP causes vasodilation 
and subsequent hypotension in the dog. Doses of up to 1.1mg/kg intravenously  or 
intramuscularly (Popovic et al. 1972) produced approximately a 15% decrease in 
MAP over 2hr, whilst intramuscular doses of 0.11mg/kg caused decreases of 
approximately 20% in MAP (Turner et al. 1974). A combination of acepromazine 
with butorphanol reflected similar decreases in MAP as a measure of cardiovascular 
function (Kojima et al. 1999). However, other studies have shown no significant 
changes in MAP after doses in combination with butorphanol or oxymorphone 
(Cornick and Hartsfield 1992). Cardiac index did not change in halothane 
anaesthetised dogs given 0.2mg/kg ACP IM (Boyd et al. 1991). 
28 
Heart rate may decrease mildly when using ACP (Popovic et al. 1972; Boyd et 
al. 1991; Kojima et al. 1999). 
Kidney function, measured in terms of glomerular filtration rate, is not 
affected by these reductions in arterial pressure (Newell et al. 1997).   
An often repeated suggestion regarding ACP is its ability to decrease the ictal 
threshold. This has not been studied. An aetiology suggested by Gross (2001) is 
stimulation of extrapyramidal motor pathways. 
Also due to -adrenergic vasodilation, body temperature drops as more blood 
flow is directed to the periphery rather than the body core (Pugh 1964). 
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1.4 Morphine 
1.4.1 History and derivation 
Morphine is the principal alkaloid of opium, which in turn is the dried form of 
the exudate of the poppy plant (Papaver somniferum). Powdered opium contains 
approximately 10% anhydrous morphine (Branson and Gross 2001).  
Opium has been used for the relief of pain since at least the dawn of recorded 
history, and its properties were well known to Greek, Roman and Arabian physicians. 
In 1680, Sydenham wrote: “Among the remedies which it has pleased Almighty God 
to give to man to relieve his sufferings, none is so universal or so efficacious as 
opium” (Hodgson 2000). Exported to the Far East in the 18th and 19th centuries, the 
economic potential of addiction to opium led to the “Opium Wars”, which, despite 
increasingly vigorous regulation of the trade, have never fully ceased.  
Morphine was first derived from opium by F.W.A. Sertrner in 1805, who 
named it after Morpheus, the Greek god of dreams (Branson and Gross 2001).  
 
1.4.2 Pharmacology 
The primary salt of morphine is morphine sulfate, and this is the form most 
commonly administered to animals (Thurmon et al. 1996; Barnhart et al. 2000b; 
Branson and Gross 2001). Opium derivatives act on opioid receptors, which are found 
in all parts of the nervous system and many peripheral tissues. The receptor subtype 
defined by its affinity for morphine is the  (Mu) receptor (Reisine and Pasternak 
1996), although morphine will also have some effects at  (Kappa) receptors, 
particularly at higher doses. Mu receptors have been further subclassified into 1 and 
2 types, the unwelcome side effects suspected as being involved with the 2 receptor , 
although both mediate analgesia (Branson and Gross 2001). The disposition of 
morphine is not affected by halothane or isoflurane anaesthesia (Steffey et al. 1993). 
Morphine is generally delivered to the dog via parenteral routes. Intramuscular 
administration leads to variable but generally high plasma concentrations compared to 
administration either orally or rectally. Bioavailability is less than 20% for oral or 
rectal administration. Intravenous administration is also commonly used (Vatner et al. 
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1975; Barnhart et al. 2000b; Branson and Gross 2001), although histamine release and 
excitation is a concern (Section 1.4.4). 
Being a full  opioid agonist, morphine does not exhibit an appreciable 
“ceiling” to its effects, which is beneficial for patients in extreme pain (Branson and 
Gross 2001).  
 
1.4.3 Therapeutic effects 
Analgesia is the primary therapeutic effect of morphine. The peak of action 
after subcutaneous or intramuscular administration of 0.1 to 0.5mg.kg-1 requires 30 to 
45min (Branson and Gross 2001), and may last 3 to 4hr, although this is undoubtedly 
dependent upon the level of noxious stimulation. Much higher doses have been 
administered, however not for the purposes of studying analgesia.  
Sedation may or may not be considered a therapeutic effect of morphine. 
Doses of up to 0.5mg.kg-1 have been administered for this purpose; such doses given 
SC or IM avoid the excitation seen at higher doses. In combination with 
acepromazine, this neuroleptanalgesia is useful as premedication for anaesthesia, or 
for procedures such as ultrasonography (Della Torre et al. 2000). 
Administration of morphine has a significant effect on requirements for 
inhaled anaesthetics. MAC for halothane or isoflurane was decreased by 35-40% by 
intravenous morphine at 1.0mg.kg-1 IV, a dose much higher than that commonly used 
in practice (Steffey et al. 1993). A similar decrease was reported after epidural 
administration of 0.1mg.kg-1 morphine in the dog (Valverde et al. 1989). The MAC 
reduction associated with a combination of acepromazine and morphine has not been 
studied. 
 
1.4.4 Side effects profile 
Addiction per se is not generally an issue for canine patients, although 
physical dependence can occur after several doses of morphine (Martin et al. 1974). 
Effects on the CNS vary widely between species. Manic effects, locomotor 
stimulation and dysphoria are common at low doses in many species, such as the cat, 
horse, pig, goat, cow and sheep (Branson and Gross 2001). Such excitation only 
occurs in dogs at high doses (Vatner et al. 1975; Robinson et al. 1988; Reisine and 
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Pasternak 1996; Branson and Gross 2001). This may include generalised seizures at 
extreme doses. In the dog, an initial rise in body temperature and subsequent 
hypothermia are attributed to direct effects on the thermoregulatory centre (Branson 
and Gross 2001). 
Vomiting is a common side effect of morphine in dogs, generally occurring 
within 10min of parenteral administration. This would appear to be centrally mediated 
(Reisine and Pasternak 1996). A generalised increase in gastrointestinal tone, and 
uncoordinated peristalsis may precipitate constipation in the medium to longer term.  
Endogenous opiates are thought to have important regulatory roles in the 
cardiovascular system (Reisine and Pasternak 1996). Morphine at 0.5mg.kg-1 IV 
induces a transient decrease in blood pressure and increase in heart rate in the dog. 
Blood pressure returns soon to baseline, and heart rate drops significantly due to 
vagotonic effects of the drug (DeSilva et al. 1978). Lower doses (0.015mg.kg-1 IV) 
may induce an initial increase in MAP (Given et al. 1986).  The canine heart is 
significantly less prone to ventricular fibrillation under its influence (DeSilva et al. 
1978). These effects appear to be centrally mediated. There is also significant 
vasoconstriction of canine coronary vasculature and reduction in coronary blood flow 
(Vatner et al. 1975). This is in sharp contrast to the human, where morphine has been 
commonly used to promote coronary blood flow.  
Respiratory depression is a hallmark of opiate use. Intravenous morphine at 
1.0mg.kg-1 caused an increase in arterial CO2 from 42.2 and 46.2mmHg to 55.1 and 
54.0mmHg under halothane and isoflurane anaesthesia respectively (Steffey et al. 
1993). Respiratory depression is not an issue for conscious dogs given normal 
therapeutic doses of morphine (Branson and Gross 2001).  
Histamine release is consistently recorded when high doses of morphine are 
delivered intravenously (Robinson et al. 1988). Whilst the histamine concentrations 
may be well in excess of those causing anaphylactice shock in humans, dogs do not 
seem to suffer the serious cardiovascular effects that should be associated with such a 
response. 
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1.5 Meloxicam 
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID). It is a 
relatively new NSAID that is characterised by its more favourable side effect profile 
and prolonged action compared to older drugs of its class. 
A primary effect common to NSAID is their suppression of the enzyme cyclo-
oxygenase (COX). This enzyme metabolises arachidonic acid into precursors for 
several important mediators of the inflammatory process collectively referred to as the 
eicosanoids (Higgins and Lees 1984). Inactivation of this enzyme by NSAID inhibits 
many of the signs of inflammation (Vane 1971; Lascelles et al. 1998; Matthews et al. 
2001). More recently, it has been elucidated that two isoenzymes of COX are present, 
labelled COX-1 and COX-2 (Donnelly and Hawkey 1997). Broadly speaking, COX-1 
is responsible for the physiological mechanisms requiring production of eicosanoid 
substances such as prostaglandins, whereas COX-2 is induced in inflammatory 
situations. Suppression of both isoenzymes, as achieved with older NSAID such as 
aspirin, led to the typical side effects of gastrointestinal ulceration and renal toxicity 
in both the human and dog (Johnston and Budsberg 1997).  
In theory, a NSAID which selectively inactivates COX-2 more than COX-1 
should result in a decrease in deleterious side effects. Meloxicam is such a drug, being 
more selective for the inducible isoenzyme than other NSAID such as carprofen 
(Engelhardt et al. 1996a; Kay-Mugford et al. 2000). However, evidence of improved 
tolerability for a COX-2 selective NSAID is yet to be shown in the dog (Johnston and 
Budsberg 1997; Forsyth et al. 1998; Matthews et al. 2001). 
Although inhibition of COX activity has been the primary focus of 
investigation into the method of action of NSAID for many years, it is clear that these 
drugs work in other ways, through both peripheral and central pathways (McCormack 
1994; Cashman 1996). There is much still to be understood as to the action of these 
drugs. 
Meloxicam has been shown to be superior to butorphanol for analgesia in dogs 
undergoing abdominal surgery (Matthews et al. 2001). No gastrointestinal or other 
side effects were noted on necropsy of these dogs. Meloxicam had no significant 
effect on cardiorespiratory variables measured in dogs anaesthetised with chloralose-
urethane (Engelhardt et al. 1996b). The effect of meloxicam on MAC for dogs 
anaesthetised with gaseous agents has not been studied, however carprofen has no 
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effect on MAC of isoflurane or halothane in the dog (Alibhai and Clarke 1996; Ko et 
al. 2000). Meloxicam did not enhance the MAC reduction caused by morphine in the 
rat (Santos et al. 2004). 
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1.6 Conclusion 
The fluorinated hydrocarbon inhalant anaesthetics have been the primary 
agents used for maintenance of general anaesthesia for the past fifty years, and are 
used in various situations for induction of anaesthesia. The development of isoflurane 
and more recently sevoflurane overcame some of the side effects seen with the older 
halothane. Whilst the biological effects of these agents have been in some areas 
extensively studied, there remains some unanswered questions, particularly in relation 
to the veterinary literature. 
The efficacy of the three inhalants for induction of anaesthesia in humans has 
been thoroughly examined. These studies have compared the three agents both in 
terms of the speed of induction and the quality of induction. Experimental studies 
using volunteers have been undertaken, as well as large studies of clinical cases. The 
agents have been compared against each other; they have also been compared to 
induction of anaesthesia with intravenous agents such as propofol. However, the 
veterinary literature contains a fewer number of studies of induction of anaesthesia 
with these agents in the dog. The only previous studies to quantify and compare the 
speed and quality of induction with these agents have been undertaken in the 
experimental situation. The limited number of clinical studies have not attempted to 
compare the agents. 
Likewise, recovery from anaesthesia with these agents has been more closely 
studied in the human than in the dog. Again, the only studies attempting to compare 
recovery after anaesthesia with these agents in the dog have been in the experimental 
environment, in animals not exposed to surgery.  
Therefore, the current study was implemented to test the following 
hypotheses: 
 
• Induction of general anaesthesia with sevoflurane would be faster and 
of better quality than that seen with either isoflurane or halothane. 
• Induction of anaesthesia with sevoflurane would be of equivalent speed 
and quality to that seen with propofol. 
• Recovery after sevoflurane anaesthesia would be faster and of better 
quality than that seen with either isoflurane or halothane. 
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• The use of acepromazine and morphine as premedication before 
anaesthesia would lead to a faster and smoother induction of 
anaesthesia. 
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Chapter 2: Materials and Methods 
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2.1 Study Objectives 
The objectives of the study were as follows: 
 
1. To compare the quality and speed of anaesthetic induction, maintenance and 
recovery with sevoflurane to those occurring with isoflurane and halothane, in 
healthy dogs undergoing routine desexing. 
2. To compare the quality and speed of anaesthetic induction, maintenance and 
recovery using intravenous propofol for induction, and sevoflurane, isoflurane 
or halothane for maintenance, in healthy dogs undergoing routine desexing.  
 
The characteristics of sevoflurane anaesthesia in the dog have been 
extensively studied in the experimental environment. This study aimed to redress the 
paucity of data related to its characteristics relative to the more established inhalant 
agents in the clinical environment.  
 
 
2.2 Experimental design 
The study was designed as a prospective clinical study. The dogs enrolled 
were young adult, healthy dogs scheduled for general anaesthesia and surgery for 
routine castration or ovariohysterectomy. 
Each dog was placed into one of twelve groups that determined the anaesthetic 
protocol employed (Table 2.1). The first part of this process was an active selection as 
to whether the dog would receive premedication or no premedication. This decision 
was based on the assessment of demeanour described below (Section 2.5.1.2.1). 
Animals scoring 1 or 2 (more excited or nervous animals) were placed in a 
premedication group. Animals scoring 3 or 4 (calmer animals) were placed in a no-
premedication group. From this point, group allocation was random, appointing an 
induction method – intravenous or inhalant – and maintenance inhalant agent – 
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halothane, isoflurane or sevoflurane. Those in which anaesthesia was induced with an 
inhalant anaesthetic agent were maintained on the same inhalant. 
 
Maintenance agent  Halothane Isoflurane Sevoflurane 
Intravenous 
induction NP P NP P NP P 
Inhalant  
induction NP P NP P NP P 
 
Table 2.1 Experimental groups  
  NP = No Premedication 
  P = Premedication 
 
One veterinarian (the author) undertook all anaesthetic inductions, and 
supervised the maintenance of and recovery from anaesthesia. 
 Dogs were enrolled from the Canine Desexing Clinic (CDC) operated by the 
Faculty of Veterinary Science, University of Sydney. The purpose of this clinic is to 
allow final year undergraduate students to gain experience in surgery and anaesthesia 
of small animals, under close supervision. The anaesthesia protocols used (Section 
2.3) were those routinely undertaken in this clinic. Of the 8 to 10 animals presented 
each day of operation of the CDC, 1 to 3 dogs were enrolled in the study. The 
selection process involved enrolling the first, third and fifth dogs brought by the final 
year students from the kennel area to the induction area. The students were unaware 
of the nature of the study.   
Young to middle aged adult dogs were enrolled. As exact ages for animals in 
the CDC were not known, an approximation was made from examination of the dogs’ 
appearance, hair coat, eyes and teeth.  
Cryptorchid dogs being desexed were included in the study, as were females 
undergoing desexing whilst in oestrus. However, animals undergoing any other form 
of non-routine desexing, or other concurrent procedures, were excluded.   
Participants were considered healthy on the basis of a routine physical 
examination, as described below (Section 2.5.1.1.1). 
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2.3 Anaesthesia protocols 
2.3.1 Premedication 
 Dogs selected into a premedication group received 0.03mg.kg-1 acepromazine1 
and 0.5mg.kg-1 morphine2, injected into the lumbar musculature midway between the 
last rib and pelvis. These two drugs were drawn up in one suitably sized syringe3, and 
injected through a 23Gx1”4 or 25Gx”5 needle, the larger needle being used for dose 
volumes in excess of 1.0ml. Animals in the no-premedication groups were not given a 
placebo injection, to retain similarity to private practice.  
After injection, premedicated animals were placed on a blanket on the floor 
and  restrained by a leash. A heat lamp6 was placed approximately one metre away 
from premedicated animals in both locations. Non-premedicated animals were held in 
similar conditions prior to anaesthetic induction, without the use of the heat lamp. 
Animals given premedication were not disturbed for at least twenty minutes following 
the injection. 
From this point onwards, animals in the premedication and no-premedication 
groups were treated identically.  
 
2.3.2 Intravenous catheterisation 
Each dog had an intravenous catheter placed in either the right or left cephalic 
vein. Catheter size was selected by the supervising veterinarian, based on the size of 
the animal and the dimensions of the cephalic vein. Either a 20Gx1.16” or 22Gx1.00” 
intravenous catheter7 was used, the smaller generally being used in dogs weighing less 
                                                 
1
 A.C.P. 2. Delvet, Seven Hills, NSW, Australia 
2
 Morphine Sulfate Injection BP 10mg/ml. David Bull Laboratories, Mulgrave, Victoria, 
Australia 
3
 1.0 and 3.0ml syringes: Terumo Syringe, Terumo (Phillipines) Corporation, 
Phillipines 
4
 Terumo Needle, Terumo Corporation, Tokyo, Japan 
5
 B-D PrecisionGlide Needle. Becton-Dickinson Medical (S) Pte Ltd. Singapore 
6
 Osram Siccatherm Bulb 275W. Osram 
7
 BD Insyte. Becton-Dickinson Medical (S) Pte Ltd. Singapore 
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than 10kg. A short T extension set8 with injection port9 was attached to the hub of the 
intravenous catheter, and the catheter/extension set was secured to the leg using 
adhesive tape10. The catheter was flushed with 0.9% saline11 to which had been added 
2IU.ml-1 heparin12.  
 
2.3.3 Induction protocols 
2.3.3.1 Inhalant agent inductions 
 Inhalant inductions were undertaken using a single anaesthetic machine13, with 
this same machine used for maintaining all cases under anaesthesia. This machine was 
equipped with a paediatric rebreathing circuit14 for all dogs less than 10kg, and a 
human adult co-axial rebreathing circuit15 for dogs in excess of 10kg. Carbon dioxide 
was removed from the circuit using soda lime16. The appropriate size for the 
rebreathing bag was considered to be that which fell within the upper and lower limits 
of the following formula: 
 
 Rebreathing bag size = (Tidal volume) x 5 
 
 Lower limit: (0.01 x (weight (kg)) x 5  (litres) 
 
Upper limit: (0.02 x (weight (kg)) x  5  (litres) 
 
The following rebreathing bag sizes were available: 0.5, 0.75, 1.0, 2.0, 3.0 
litres17.  
                                                 
8
 Abbott Lifeshield Microbore Extension Set. Abbott Laboratories, North Chicago, IL, 
USA 
9
 IN-Stopper. B.Braun Melsungen AG, Germany 
10
 Kendall Curity Standard Porous Tape. The Kendall Company, Mansfield, MA, USA 
11
 0.9% Sodium Chloride. Baxter Healthcare Pty Ltd, Old Toongabbie, NSW, Australia 
12
 Heparin Injection BP. David Bull Laboratories, Mulgrave, Victoria, Australia 
13
 The Stinger. Advanced Anaesthesia Specialists, Gladesville, NSW, Australia 
14
 Paediatric rebreathing circuit. Endovations, Leichhardt, NSW, Australia. 
15
 Universal F2. King Systems Corporation, Noblesville, IN., USA.  
16
 Drägersorb 800Plus. Dräger Medical AG & Co KGaA, Lübeck, Germany 
17
 Ohmeda Medical, Laurel, MD, USA. 
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The selected inhalant was delivered from a vaporiser mounted18 in an out-of-
circuit configuration; halothane19, isoflurane20 and sevoflurane21 were each delivered 
from a single vaporiser22,23,24 throughout the study. Visualisation of the sight glass of 
each vaporiser ensured it was at least half full before each anaesthetic procedure was 
commenced. All three vaporisers had been calibrated within the twelve months prior 
to the commencement of data collection. Their output at each dial setting was 
measured at this calibration. Calibration was assessed again at the end of the data 
collection period. 
All inhalant inductions were performed using a clear plastic mask25 which 
covered the muzzle of the dog. The smallest mask which would accommodate the full 
muzzle was used. A rubber diaphragm surrounding the aperture of the mask improved 
the seal possible with the mask in place. The mask was not placed over the dog’s 
muzzle until the commencement of the induction process. Between the mask and the 
patient connector of the circuit was placed an adaptor which provided a coupling for 
the sampling hoses of the capnograph and end-tidal anaesthetic agent monitor (Section 
2.5.3.1.2). Before connection of mask and adaptor, the anaesthetic machine was 
checked for leaks by pressurising the circuit with oxygen using the emergency oxygen 
bypass valve. The machine was considered safe if the pressure on the machine 
mounted pressure gauge fell less than 5cmH2O in 20seconds, from an initial 
20cmH2O. 
Induction of general anaesthesia was undertaken with dogs on the floor of the 
induction area when they weighed in excess of 20kg. Patients less than 20kg were 
held on a table during induction. Smaller dogs were held by a veterinary nurse and the 
veterinarian administering the anaesthetic agent. For larger dogs an additional person 
                                                 
18
 Selectatec vaporiser mount. BOC Australia, Annandale, NSW, Australia 
19
 Rhodia Halothane. Merial Australia Pty Ltd, Parramatta, NSW, Australia 
20
 Isoflo. Abbott Australasia, Kurnell, NSW, Australia 
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 SEVOrane. Abbott Australasia, Kurnell, NSW, Australia 
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 Halothane vaporiser: FluoTec 3, Cyprane, Keighley, England. Remanufactured by 
Advanced Anaesthesia Specialists, Gladesville, NSW, Australia 
23
 Isoflurane vaporiser: IsoTec3. Cyprane, Keighley, England. Remanufactured by 
Advanced Anaesthesia Specialists, Gladesville, NSW, Australia. 
24
 Sevoflurane vaporiser: Blease Datum Series B. Blease, Chesham Bucks, England 
25
 Animal mask. GaleMed Corporation, Taiwan. 
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was enlisted to restrain the dog’s hindquarters only when necessary. The minimum 
amount of restraint required was used, to minimise the stress on the patient. 
At the point of commencement of the inhalant induction process, the oxygen26 
flow was switched on, and set to 3.0 l.min-1. This flow rate ensured the anaesthetic 
concentration inspired by the patient approached the setting on the vaporiser as 
rapidly as possible, and minimised any rebreathing of expired air within the mask. 
The mask was immediately placed over the dog’s muzzle and a stopwatch27 was 
started at this time. At this stage, no anaesthetic agent entered the circuit, the aim 
being to increase the patient’s oxygen reserve prior to anaesthetic administration. No 
nitrous oxide or other gases were used at any stage. 
At two minutes after commencement, the anaesthetic vaporiser was switched 
on, directly to its maximum rated output. For the halothane and isoflurane vaporisers, 
this was 5.0%. For the sevoflurane vaporiser, the value was 8.0%. This output was 
maintained for the duration of the induction process, with no abatement of the 
vaporiser output until after endotracheal intubation. 
The level of restraint upon the animal was increased only as needed to 
maintain the animal’s head within the mask, though no means other than manual 
restraint were employed. If the dog withdrew its head from the mask, the mask was 
replaced over the muzzle immediately, with a minimum of additional restraint. 
 Inhalant induction was abandoned only after the animal had made at least 
three vigorous attempts to withdraw its head from the mask, combined with 
movements of the legs and torso, making restraint difficult or impossible, and showed 
obvious signs of distress. Such a patient was noted as an “abandoned inhalant 
induction” and anaesthesia was induced using propofol as per the intravenous 
induction protocol below (Section 2.3.3.2).   
As the dog relaxed, it was placed into sternal recumbency in preparation for 
endotracheal intubation. Judgement of preparedness for endotracheal intubation was 
made by observing respiratory rate and pattern, eye movement and position, response 
to light tapping of the medial commissure of the eyelids (palpebral reflex), jaw tone 
and general muscle tone. When the administering veterinarian considered the animal 
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 Oxygen Medical EP Grade. Air Liquide Healthcare Pty Ltd, Annandale, NSW, 
Australia 
27
 Electronic Clock Timer. Tandy Australia, Regents Park, NSW, Australia 
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ready for endotracheal intubation, the oxygen flowmeter was turned off and the mask 
removed. 
The veterinary nurse held the dog’s mouth with one hand on the upper jaw and 
the other hand extending the tongue over the lower incisors. A laryngoscope28 with a 
suitably sized blade was used to improve visualisation of the larynx, and an 
endotracheal tube of optimal diameter was selected and positioned. It was secured in 
place with gauze tape29.  
If the patient made one or more attempts to swallow or resist positioning 
during the intubation procedure, the laryngoscope was removed and the mouth closed. 
The induction mask was replaced over the dog’s muzzle and the oxygen flowmeter 
reset to 3.0 l.min-1. This was considered a failed intubation attempt. The patient was 
allowed to continue inhaling the induction agent until it again reached a level of 
anaesthesia considered suitable for endotracheal intubation, when intubation was 
again attempted. 
Following successful endotracheal intubation, the induction mask was 
removed from the breathing circuit of the anaesthetic machine and the circuit 
connected to the endotracheal tube. Dogs induced on the floor were lifted onto the 
induction and surgical preparation table before being connected to the breathing 
circuit. Oxygen flow was recommenced at 3.0 l.min-1, the vaporiser output remaining 
at the maximum rated output. The cuff of the endotracheal tube was filled with room 
air whilst the circuit was pressurised to 15cmH2O until no gas leak around the 
endotracheal tube was audible.  
The dog was maintained in sternal recumbency until the animal was 
sufficiently anaesthetised to be moved into lateral recumbency without causing undue 
stimulation. The decision as to when to decrease the vaporiser output was based on 
response to this movement, palpebral reflex and muscle tone of the jaw. When both 
jaw tone and palpebral reflex were considerably reduced or absent, vaporiser output 
was adjusted to a value twice the previously published MAC for that agent, rounded 
to the nearest 0.5%. This equated to 1.5% for halothane, 3.0% for isoflurane and 4.5% 
for sevoflurane. This vaporiser output was maintained for a further 5min, unless signs 
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 Laryngoscope. Heine Optical, Herrsching, Germany. 
29
 Tensofix 5cm. Smith & Nephew Medical Fabrics Ltd, Brierfield, England 
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of unacceptably light anaesthesia were detected. A dose equivalent to 1.0mg.kg-1 of 
propofol was administered IV if unacceptably light anaesthesia persisted at this point. 
The oxygen flowmeter was decreased to a flow equal to 20ml.kg-1.min-1 ten 
minutes after successful intubation, with a minimum flow of 1.0 l.min-1 oxygen being 
used. Although this minimum value resulted in oxygen flow well above standard flow 
rates for rebreathing circuits for smaller dogs, this minimum value was raised on the 
basis that the capnograph and end-tidal anaesthetic monitor continuously withdrew at 
least 500ml.min-1 gas from the circuit (Section 2.5.3.1.2).  
Any dog which remained apnoeic for a period of greater than 30sec was 
ventilated by hand at a rate of 4breaths.min-1. A positive pressure of 10cmH2O was 
the target during these artificial breaths. 
From this point, the vaporiser output was adjusted based on standard criteria 
for the depth of anaesthesia, as discussed below (Section 2.3.4). The animal was then 
instrumented as discussed below, and prepared for surgery. 
 
2.3.3.2 Intravenous agent inductions 
Cases enrolled into an intravenous induction group were given propofol30 for 
induction of general anaesthesia. A volume equalling 6mg.ml-1 was drawn up into an 
appropriately sized syringe31 with needle32. As with inhalant inductions, dogs in 
excess of 20kg bodyweight were induced on the floor, those less than this weight were 
induced on a table where they would remain until being moved to the surgery table. 
All dogs were initially held by a veterinary nurse, with an additional person used to 
hold the hindquarters of larger dogs only when necessary. The objective was to use a 
minimal dose of propofol which would allow endotracheal intubation of the animal 
without overt signs of resentment. Such signs would include gagging, coughing, 
chewing or vigorous head movement. 
After confirming patency and proper placement of the intravenous catheter 
with a bolus of heparinized saline, a bolus of 2mg.ml-1 propofol was injected. The 
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 Propofol Injection. Abbott Australasia, Kurnell, NSW, Australia 
31
 3ml, 5ml, 10ml, 20ml syringe: Terumo Syringe, Terumo (Phillipines) Corporation, 
Phillipines 
32
 22Gx1.00” Terumo Needle, Terumo Corporation, Tokyo, Japan 
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stopwatch was started at the commencement of this injection. Propofol was injected 
rapidly, at approximately 1ml.sec-1, and was followed by 1.0ml of heparinized saline 
to flush the intravenous catheter clear of propofol.  
Following this bolus, the patient was observed. Preparedness for endotracheal 
intubation was based on respiratory rate and quality, eye position, muscle tone and 
response to opening of the mouth. The initial bolus was given a maximum of 45sec to 
reach peak effect.  
A further bolus of 1mg.kg-1 was delivered as above if the effect of the initial 
injection were considered insufficient, and the results observed. Further doses of 
1mg.kg-1 were delivered in this manner at 45sec intervals until the animal was 
adjudged ready for intubation.  
Endotracheal intubation was performed as for inhalant inductions. Following 
successful intubation the patient was connected to the anaesthetic machine and the 
tube cuff inflated. Patients induced and intubated on the floor were moved onto the 
table prior to connection. As with dogs induced with an inhalant agent, those less than 
10kg bodyweight breathed through a paediatric rebreathing circuit, those heavier 
through a co-axial rebreathing circuit. The anaesthetic machine was set up as 
described for inhalant inductions. No inhalant agent entered the circuit prior to 
connection to the intubated animal. 
Upon connection, the oxygen flow into the circuit was set to 3.0 l.min-1. The 
inhalant agent vaporiser output was then set to an initial value of 2.0% for halothane, 
3.0% for isoflurane, and 4.5% for sevoflurane. This output was maintained for 5 
minutes. These delivered doses for isoflurane and sevoflurane equated to twice 
previously published MAC doses, rounded to the nearest 0.5%. The slightly higher 
dose of halothane compared to that used in the inhalant agent groups at this point was 
used to shorten the onset of halothane anaesthesia, due to the ultra-short action of 
propofol. 
From this point on, animals in the intravenous induction groups were treated 
identically to those in inhalant induction groups. A single exception was the treatment 
of animals becoming unacceptably light under anaesthesia soon after intubation. 
Patients demonstrating gross purposeful movements, swallowing or chewing on the 
endotracheal tube within twenty minutes from commencement of induction were 
given a further dose of propofol to improve the transfer of anaesthesia from the 
intravenous induction to the inhalant maintenance agent. This was achieved with an 
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initial bolus of 1mg.kg-1 propofol intravenously. Further 1mg.kg-1 boluses were to be 
given at 45sec intervals until signs of unacceptably light anaesthesia were abolished.  
As with those in inhalant induction protocols, the dog was then moved into 
lateral recumbency, instrumented as discussed below, and prepared for surgery. The 
oxygen flow rate was decreased to 20ml.kg-1.min-1 ten minutes after successful 
intubation, with a minimum flow rate of 1.0 l.min-1, as described for inhalant 
inductions. 
 
2.3.4 Maintenance of anaesthesia 
Anaesthesia was maintained throughout the surgery using only the selected 
inhalant agent in oxygen. Adjustment of vaporiser output was controlled by the 
veterinarian in charge of the anaesthetic (the author). The decision to increase or 
decrease the concentration of inhaled anaesthetic agent was made based on standard 
criteria for assessing depth of anaesthesia. These included heart rate, respiratory rate 
and pattern, pulse quality, mucous membrane colour, palpebral reflex, jaw tone and 
response to movement and surgical stimulation. The goal was to achieve a level of 
anaesthesia just sufficient to allow the desexing surgery to be undertaken without 
evidence of conscious response, subconscious movement or excessive sympathetic 
nervous system tone from the patient.  
Instrumentation, clipping of hair and preparation for surgery were undertaken 
on the induction table, before movement of the patient to the surgical table. 
Movement required disconnection of the circuit for approximately 10sec. 
No attempt was made to reduce the concentration of inhaled anaesthetic agent 
close to the completion of surgery. The vaporiser output was maintained at the same 
output as had been selected by that time. 
Intravenous fluid therapy was administered to all animals. A crystalloid 
replacement fluid33 was infused at the rate of 10ml.kg-1.hr-1, using the intravenous 
catheter placed prior to induction. Administration was commenced as soon as possible 
after induction and ceased at the end of surgery. Gravity feed giving sets were used, 
an adult set34 (20drops.ml-1) for dogs in excess of 9kg bodyweight, and a paediatric 
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 Plasma-Lyte 148 Rep. Baxter Healthcare, Old Toongabbie, NSW, Australia 
34
 Solution Administration Set (20drops/ml). Baxter Healthcare Pte Ltd, Singapore 
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system (60drops.ml-1) with burette35 for those less than 9kg. Body temperature was 
conserved via the use of an electric heat pad36 on both the induction and surgery 
tables, warm water bottles in the form of 0.5 and 1.0litre intravenous fluid bags 
converted for the purpose, and blankets. A bland ophthalmic ointment37 was 
administered to the eyes.  
Each patient received 0.2mg.kg-1 meloxicam38, intravenously soon after first 
surgical incision. Each dog also received routine vaccination39 and antibiotics40 prior 
to first surgical incision. The antibiotics and vaccination were not considered to have 
any influence over the nature of the anaesthetic or the recovery period. 
 
2.3.5 Recovery 
At the completion of surgery, defined as cutting of the last skin suture, the 
vaporiser setting was switched to “Off”, and the oxygen fresh gas flow set to 3.0 
l.min-1. The rebreathing bag was evacuated once into the gas scavenge line. The dog 
was positioned in lateral recumbency. The only additional stimulation the dog 
received for the next ten minutes was cleaning of the surgical site with saline soaked 
gauze41, and the removal of the arterial catheter and oesophageal temperature probe 
(Sections 2.5.3.1.1, 2.5.3.1.3).  
The dog remained connected to the anaesthetic machine circuit for ten minutes 
following end of surgery unless it was adjudged ready for extubation within that time.  
After ten minutes, or immediately following extubation if performed within that 
period, the dog was disconnected from the circuit and moved to the recovery area. 
The animals were placed on a blanket on the floor, with a heat lamp stationed 
approximately 1m away. They were supervised to ensure they inflicted no harm to 
themselves during this period.  
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 Lacri-Lube. Allergan Australia, Sydney, Australia 
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Dogs were considered ready for extubation when they fulfilled one of the 
following criteria: conscious chewing on the endotracheal tube, conscious 
swallowing, or lifting the head. An increase in respiratory rate, change in respiratory 
pattern or blinking was not considered sufficient for extubation. 
Following extubation, dogs were not further handled until after they had stood, 
unless they required manual restraint or support to avoid injuring themselves during 
recovery.  
The point at which the animal stood was the last piece of data to be collected, 
and care of the dog following this time was as per routine for the CDC, with three 
postoperative examinations over the following 18-24hr, before the dogs were 
discharged from the clinic.  
 
2.3.5.1 Supplementary analgesia 
During recovery, dogs were observed for quality of recovery. Any dog 
showing marked signs of pain was given supplementary analgesia in the form of an 
intramuscular injection of 0.4mg.kg-1 morphine. Such cases were given the lowest 
score for recovery quality (Section 2.5.4.2.1).  
 
2.4 Surgery 
 
Dogs were desexed using routine surgical techniques. Ovariohysterectomy 
was performed via a ventral midline approach with the dog positioned in dorsal 
recumbency. Ovarian ligaments were ruptured by hand and the pedicles ligated using 
absorbable suture material42. The uterus was ligated with absorbable suture and 
transected just cranial to the cervix. Three layer closure of the abdomen was 
performed with continuous suture patterns in the linea alba and subcutaneous layers, 
and cruciate sutures of nonabsorbable suture material43 in the skin.  
Male dogs were castrated through a prescrotal incision with the patient 
positioned in dorsal recumbency. Both open and closed techniques were used. Two or 
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 PDS II. Ethicon, Inc., Somerville, NJ, USA  
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 Ethilon. Ethicon, Inc., Somerville, NJ, USA 
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three layer closures were undertaken, with an optional continuous layer in the scrotal 
tunic, followed by a continuous subcutaneous layer and nonabsorbable cruciate 
sutures in the skin. 
Each surgery was performed by two final year veterinary science students 
from the University of Sydney, under the direct supervision of a veterinarian. No 
other surgical procedures were undertaken. 
 
 
2.5 Data Collection 
 
2.5.1 Prior to anaesthesia 
2.5.1.1 Quantitative data 
2.5.1.1.1  General health status 
Data collection prior to induction of general anaesthesia consisted of a routine 
clinical pre-anaesthesia examination, including auscultation of the heart and lungs, 
palpation of the peripheral pulse, assessment of mucous membrane colour and 
capillary refill time, rectal temperature, abdominal palpation and general demeanour. 
Percutaneous venipuncture of a jugular vein was performed, with 1.0ml of blood 
placed in an evacuated tube containing CaEDTA as an anticoagulant, and 1.0ml in an 
uncoated evacuated tube. This sample provided a preanaesthetic baseline for any 
patient that had intra- or post-operative complications.  
 
2.5.1.2 Qualitative data 
All qualitative assessments were made by the author. 
 
2.5.1.2.1 Demeanour 
Each dog was assessed as to its overall demeanour, based on response to initial 
handling for physical examination and jugular venipuncture. This assessment was 
marked in the form of a number between 0 and 4 inclusive, as follows: 
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Score 0: Abnormal, signs of depression (would be excluded from study) 
Score 1: Anxious and aggressive, difficult to handle, requiring continual firm restraint, 
including muzzle. 
Score 2: Anxious, frightened, requires generally firm restraint, but not aggressive. 
Score 3: Nervous and/or excitable, requires less restraint. 
Score 4: Calm, friendly, easy to handle, minimal restraint required. 
 
This data was used as part of the active selection of dogs into premedication or 
no-premedication groups, as described above (Section 2.2).  
 
2.5.1.2.2 Sedation 
Dogs that were premedicated were scored just prior to induction of general 
anaesthesia as to their sedation and resistance to handling. Specifically: 
 
Score 3: Sedation profound – resistance none: Dog is recumbent, can be aroused but not 
willing to stand and walk. No resistance to being moved or manipulated. Seems barely aware of 
being manipulated. 
Score 2: Sedation moderate – slight resistance: Dog recumbent when not aroused. Will stand 
and walk if encouraged. Possibly some resistance when manipulated and moved however only 
one person required to move and restrain dog. 
Score 1: Sedation slight – resistance moderate: Dog obviously more relaxed and calm 
compared to prior to premedication. Walks easily, not necessarily recumbent when not being 
aroused. May require two people to manipulate and restrain dog. 
Score 0: Sedation none – resistance profound: Dog is excitable, unchanged from prior to 
premedication. Marked force may be required for moving and manipulating the patient. 
 
 
2.5.2 During induction of general anaesthesia 
2.5.2.1 Quantitative data 
During the induction process, qualitative and quantitative measurements were 
undertaken. A person not involved in restraining or medicating the animal recorded 
the relevant data on the data collection sheet. This person also controlled the 
stopwatch.  
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The time of commencement was set as the time when the induction mask was 
first placed over the dog’s muzzle to commence preoxygenation, for inhalant 
induction, or, for intravenous inductions, the point at which injection of propofol was 
started. The stopwatch was started at this point, with this device then counting 
upwards from zero in hours, minutes and seconds. The stopwatch was not stopped 
from this point until the end of data recording postoperatively. All times were 
recorded to a resolution of 1sec as they appeared on the stopwatch. 
The following quantitative data was collected during the induction process. 
 
 
2.5.2.1.2 Time to intubation 
The time at which the laryngoscope was removed from the mouth immediately 
following successful endotracheal intubation of the patient.  
 
2.5.2.1.3 Intubation attempts 
An unsuccessful attempt to intubate an animal, which required an additional 
dose or doses of the induction agent to be given before intubation could again be 
attempted, was considered a failed attempt. Incorrect endotracheal tube size selection 
requiring a change of tube prior to successful intubation was not considered a failed 
attempt if no further induction agent was required before successful intubation was 
achieved. The number of failed attempts, plus one successful attempt, was the total 
recorded. 
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2.5.2.1.4 Dose of propofol prior to intubation 
The total dose of propofol, in milligrams, administered prior to successful 
endotracheal intubation for patients undergoing intravenous agent induction. 
 
2.5.2.1.5 Dose of propofol post-intubation 
Any further dose of propofol given soon after successful endotracheal 
intubation. Such a dose would be delivered to maintain a minimum acceptable level of 
anaesthesia during the period whilst the selected inhalant agent was achieving an 
appropriate anaesthetic concentration within the patient (Section 2.3.3.1,  2.3.3.2).  
 
 
2.5.2.2 Qualitative data 
2.5.2.2.1 Tolerance of mask 
 Patients induced with an inhalant agent were scored for tolerance of mask. 
This represented the response of the dog to the induction mask in the period of 
preoxygenation, and did not include any response noted after inhalant anaesthetic 
entered the breathing circuit. It was scored on the following scale: 
Score 4.Excellent: No attempts made to remove head from mask. Minimal restraint required 
to hold dog in position – one nurse sufficient. Respiratory rate and pattern close to normal within 
30sec of mask placement. 
Score 3. Good: No more than two attempts to withdraw head from mask, mask easily replaced 
after withdrawal. Minimal restraint required – one nurse sufficient. Respiratory rate and pattern 
possibly disrupted from normal throughout preoxygenation.  
Score 2. Fair: More than two attempts to withdraw head from mask, may be difficult to 
replace mask after withdrawal. Greater level of restraint required – additional person may be 
required for larger dogs, firm “scruffing” required. Respiratory rate and pattern disrupted 
throughout preoxygenation.  
Score 1. Poor: More than two attempts to withdraw head from mask, reapplication of mask 
difficult. Withdrawal attempts include use of limbs to remove mask. Greater level of restraint 
required. Respiratory rate and pattern disrupted throughout preoxygenation. Dog visibly 
distressed by mask. 
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Score 0. Unacceptable: Unable to keep mask in place and/or restrain dog in position. Dog 
obviously distressed and/or aggressive. Mask induction abandoned – move to intravenous 
induction.  
 
 
2.5.2.2.2 Quality of induction 
This variable represented the nature of the entire induction process to the point 
of successful endotracheal intubation. It was scored on the following scale: 
Score 4. Excellent: Smooth and rapid transition from conscious to anaesthetised with minimal 
resistance in terms of movement. Minimal restraint required – one nurse sufficient. Muscle relaxation 
sufficient for easy opening of mouth by nurse for endotracheal intubation.  
Score 3. Good: Transition from conscious to anaesthetised associated with some movements 
requiring restraint by a single assistant. Movements do not interfere with process of endotracheal 
intubation, muscle relaxation sufficient for easy opening of mouth.  
Score 2. Fair: Moderate excitation present during transition from conscious to anaesthetised, 
in terms of gross movement, vocalisation, urination or defecation. Firm restraint required – an 
additional person required for larger dogs. Poor to medium muscle relaxation, making opening mouth 
for endotracheal intubation more difficult.  
Score 1. Poor: Marked excitation, in terms of gross movement and struggling, vocalisation, 
urination or defecation. Firm restraint required but still difficult to retain dog in position. Poor muscle 
relaxation making opening mouth difficult. Dog shows signs of distress.  
Score 0. Unacceptable: Marked excitation and struggling, and/or aggression. Unable to 
maintain dog in position despite firm restraint. Dog shows obvious signs of distress. Inhalant induction 
protocols – abandon, move to intravenous induction. Intravenous induction protocols – abandon, 
reassess suitability of dog for anaesthesia at this time.  
 
 
2.5.2.2.3 Quality of transfer 
A measure of the adequacy of anaesthesia in the first twenty minutes 
following successful endotracheal intubation – the period of transfer between the 
induction agent and the maintenance agent. Scored on the following scale: 
Score 4. Excellent: Patient remains well anaesthetised throughout the period. Respiratory 
rate and pattern is within normal ranges for an anaesthetised dog, initial apnoea lasts no longer than 
30sec. Palpebral reflex may or may not be present, jaw tone medium to slack. No conscious or 
unconscious movement. Dog may be moved from lateral to dorsal recumbency without evident 
lightening of anaesthesia.  
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Score 3. Good: Patient remains well anaesthetised. Respiratory rate and pattern may be 
somewhat irregular – either apnoea prolonged more than 30sec, or more vigorous “panting” type 
breathing. No conscious or unconscious movements whilst dog’s position is unchanged, mild 
unconscious movements may be observed when position is changed.  
Score 2. Fair: Patient becomes notably lighter under anaesthesia during the period. 
Respiratory pattern and rate are irregular. Some conscious or unconscious movements occur when 
patient position remains unchanged. Conscious swallowing or chewing on endotracheal tube occurs. 
Palpebral reflex present for most of the period, jaw tone at some stage tight. For patients in 
intravenous induction protocols, a single further dose of propofol is required to avoid an unacceptable 
lightening of anaesthesia.  
Score 1. Poor: Patient becomes notably lighter under anaesthesia. Respiratory rate and 
pattern irregular. Conscious movements occur, chewing or conscious swallowing on endotracheal tube 
occurs. Restraint may be necessary to avoid patient injuring self or staff. For patients in intravenous 
induction protocols, one or more additional doses of propofol are required.  
 
 
2.5.3 During maintenance of anaesthesia 
2.5.3.1 Quantitative data 
2.5.3.1.1 Cardiovascular variables 
Heart rate (HR), peripheral arterial haemoglobin saturation (SpO2), systolic 
arterial pressure (SAP), diastolic arterial pressure (DAP) and mean arterial pressure 
(MAP) were monitored throughout anaesthesia.  
As soon as feasible following the induction of anaesthesia, a transmission 
pulse oximeter probe was placed on a portion of the tongue at least 5mm in thickness 
to measure SpO2. This was expressed as a percentage. The electronic monitor44 which 
displayed a plethysmogram representation of SpO2, blood pressure and temperature 
data, provided no means for calibration of the pulse oximeter. A single probe was 
used for all dogs. 
Blood pressures were measured directly. An over-the-needle catheter45, either 
22Gx1.00”, or 20Gx1.16”, was placed into the dorsal metatarsal artery. If attempts to 
place this catheter were unsuccessful by 30minutes after induction, blood pressure 
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 BD Insyte. Becton-Dickinson Medical (S) Pte Ltd. Singapore. 
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measurement was abandoned. Such cases were, however, not excluded from the 
study. Connected to this intra-arterial catheter was a short T extension set46, and two 
150cm minimum volume extension sets47 designed for blood pressure measurement 
separated by a three way stopcock48. The distal end of this apparatus was then 
connected to the blood pressure transducer49, a quartz crystal transducer which 
produced a continuous waveform on the electronic monitor. This transducer kit 
included a continuous flush mechanism, which allowed a steady low flow of 
heparinised saline through the arterial line to prevent clotting. Arterial blood pressures 
were measured in millimetres of mercury. The transducer was zeroed to atmospheric 
pressure prior to the commencement of data collection in each case. A single 
transducer was used for all dogs.  
Heart rate was generated by the electronic monitor from pulse oximeter data 
until the blood pressure transducer was operational. This value was cross checked by 
manual pulse palpation or cardiac auscultation if the pulse oximeter waveform was 
not consistent with clear pulse detection. An SpO2 reading was not recorded in such 
instances.  
 
2.5.3.1.2 Respiratory variables 
Respiratory variables measured throughout anaesthesia were respiratory rate, 
end-tidal carbon dioxide, and inspiratory and end-tidal expiratory inhalant anaesthetic 
concentrations.  
End-tidal partial pressure of carbon dioxide and respiratory rate were 
measured by capnograph50. Inspiratory and end-tidal expiratory concentrations of 
inhalant anaesthetic were measured by a separate gas analyser51. End-tidal carbon 
dioxide was recorded in millimetres of mercury. Inhalant agent concentrations were 
measured in volumes per cent. An adaptor placed between endotracheal tube and 
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 Abbott Lifeshield Microbore Extension Set. Abbott Laboratories, North Chicago, IL, 
USA. 
47
 Extension Tubing DCO150HP. Dispo-Med, Malaysia. 
48
 ThreeWay Stopcock. Baxter Healthcare Corporation, Deerfield, IL, USA. 
49
 Monitoring Kit, Transpac IV. Abbott Critical Care Systems, Sligo, Ireland. 
50
 Ohmeda 4700 OxiCap Monitor. Ohmeda, Louisville, CO, USA. 
51
 Ohmeda 5330. Ohmeda, Louisville, CO. USA. 
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breathing circuit provided a port for continuous gas sampling, at a rate of 250ml.min-1 
minimum for the end-tidal anaesthetic monitor, and 250ml.min-1 for the capnograph. 
This adaptor was placed on the breathing circuit prior to induction, and per the 
operating manuals, both machines were switched on at least 30minutes prior to 
induction to allow readings to stabilise. Calibration was undertaken as recommended 
by the manufacturer of both machines, using gases of known concentration. 
Calibration was undertaken weekly for the capnograph, and monthly for the end-tidal 
anaesthetic monitor. Monthly adjustment of barometric pressure for the end-tidal 
anaesthetic monitor was addressed, using a mercury column barometer as reference. 
During anaesthesia, respiratory rate was cross-checked by visual measurement of 
rebreathing bag movement over a 30sec period. 
 
2.5.3.1.3 Temperature 
An oesophageal temperature probe was placed soon after induction. It was 
advanced to a point approximately equivalent to the thoracic inlet. This probe was 
connected to the same monitor as provided the blood pressure and SpO2 data, with 
readings in degrees Celsius to a resolution of 0.1°C. The monitor provided no means 
for calibration of this probe, however its readings were compared to reference values 
in a water bath containing a calibrated thermometer. The same probe was used for all 
cases.  
 
2.5.3.1.4 Frequency of data collection 
During maintenance of anaesthesia, the above variables were recorded every 
five minutes for the first hour, then every ten minutes. These intervals were measured 
from commencement of induction. A first reading was taken as soon as the pulse 
oximeter, capnograph, end-tidal anaesthetic monitor and temperature probe were 
attached, with readings then taken at the five minute intervals from induction.  
 
2.5.3.1.5 Other quantitative data 
During the maintenance phase of anaesthesia, two other data points were 
recorded. Time of incision represented the time at which the initial surgical incision 
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was made. End of procedure time was the conclusion of surgery, defined as the 
completion of the last skin suture. As mentioned previously, this was also the time at 
which the inhalant anaesthetic vaporiser was switched off. These times were recorded 
to a resolution of 1 second, timed from commencement of induction.  
 
2.5.3.2 Qualitative data 
No qualitative data was recorded during the maintenance phase of anaesthesia. 
 
2.5.4 Recovery from anaesthesia 
2.5.4.1 Quantitative data 
2.5.4.1.1 Time of extubation 
 The time the endotracheal tube was removed, following the protocol outlined 
above (Section 2.3.5). 
 
2.5.4.1.2 Time to righting 
Following extubation, the time at which the dog first moved itself into sternal 
recumbency and was able to maintain such a position. Momentary head raising was 
not considered righting. 
 
2.5.4.1.3 Time to standing 
The time the dog first raised itself to a standing position. 
 
2.5.4.2 Qualitative data 
2.5.4.2.1 Quality of recovery 
The final piece of data to be considered was the quality of recovery. This 
encompassed the period from the discontinuation of inhalant anaesthesia to any 
responses demonstrated at or soon after the patient stood after anaesthesia. It was 
scored on the following scale: 
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Score 4. Excellent: Smooth transition from anaesthesia to full consciousness. No paddling, 
tremors or other unconscious movements. No vocalising. Salivation normal, not excessive. 
Transfers from lateral recumbency to sternal with one or two attempts. No obvious signs of pain.  
Score 3. Good: Mostly smooth transition from anaesthesia to full consciousness. Some mild 
unconscious movements may be seen. No vocalising. Salivation may be increased, some general 
signs of pain may be witnessed. More than two attempts may be necessary for transition from 
lateral to sternal recumbency. 
Score 2. Fair: Transition from anaesthesia to full consciousness is not smooth. Moderate 
paddling or other unconscious movements, persist well into recovery period. Vocalisation present. 
Patient has difficulty positioning itself, may thrash about for short periods. Manual restraint may 
be required for short periods. Hypersalivation possibly present. Moderate to marked signs of pain.  
Score 1. Poor: Rough transition from anaesthesia to full consciousness. Regular unconscious 
movements persist well into consciousness, thrashing for sustained periods. Animal will injure 
itself without manual restraint, may respond aggressively to restraint. Marked signs of pain. 
Hypersalivation. Sustained vocalisation.  
 
 
2.6 Statistical Analysis 
All analyses excepting the induction dose of propofol (Section 2.6.3) were 
performed using the computer program SPSS52. Propofol dose analysis was performed 
using the computer program Minitab53. 
 
2.6.1 Time to intubation 
All times were converted to seconds for analysis. A two-way analysis of 
variance (ANOVA) was undertaken to analyse times to intubation, with 
premedication and induction agent as the independent variables. Interaction between 
induction agent and premedication was investigated. Where F values were significant, 
post-hoc tests of Least Significant Difference were used.  
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2.6.2 Quality of induction 
Scores for quality of induction were collapsed into a two-level variable. All 
scores less than 4 (excellent) were reclassed as category 1. All scores of 4 (excellent) 
were reclassed as category 2. Logistic regression was then performed on this new 
variable. A Hosmer-Lemeshow test was performed to confirm goodness of fit to the 
model, and residuals were inspected.  
 
2.6.3 Propofol dose for induction 
Doses were converted to mg.kg-1 using the weights recorded prior to 
anaesthesia. A two sample T-test was performed on this data. Because of the 
heteroscedasticity of the two groups, this data was also analysed using a Mann-
Whitney U test. The data was also transformed by natural log to improve normality of 
the distribution, and a two sample T-test performed on the transformed data.  
 
2.6.4 Time to righting  
A natural log transformation was undertaken to normalise the data. A two-way 
ANOVA was performed, with premedication, induction agent, procedure time and 
temperature at procedure end as the independent variables. Interaction between these 
variables was investigated. Where F values were significant, post hoc tests of Least 
Significant Difference were used. 
 
2.6.5 Time to standing 
This data was analysed using a similar model as time to righting (Section 
2.6.4). 
 
 
2.7 Costing of agents 
The costs involved in undertaking inhalant induction with the three inhalant 
agents was calculated, based on the method described in Steffey (1996) for 
determination of the volume of liquid volatile agent consumed. The following 
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assumptions were used. The mean time to intubation for all cases induced with each 
agent was used, with oxygen flow rates and vaporiser settings as described above 
(Section 2.3.3.1). Physical data for the agents was as summarised in Table 1.1. 
Ambient temperature was assumed to be 20°C. 
The cost involved in induction with propofol was also calculated. The mean 
dose for cases induced with and without premedication was used.  
The cost involved in maintaining anaesthesia in a patient using each of the 
three inhalant agents was calculated, assuming a vaporiser setting of 1.5.MAC based 
on the upper limit of MAC values expressed in Table 1.2, at a total fresh gas flow of 
1.0 l.min-1. The method described in Steffey (1996) was again used for determination 
of liquid anaesthetic agent used.  
Costs for each agent were obtained from a veterinary wholesaler54, and 
represent the GST-inclusive price to the University Veterinary Centre, Camden, in 
August, 2004. One 250ml bottle of halothane, isoflurane or sevoflurane cost A$43.08, 
A$166.25, and A$462.00 respectively. One 20ml (200mg) vial of propofol cost 
A$14.95. Vaporiser costs were obtained from a veterinary equipment dealer55 in 
August 2004. 
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61 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3: Results 
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3.1 Cases enrolled 
Seventy-one dogs were enrolled into the study during the data collection 
period. This represents those considered healthy on the basis of physical examination 
prior to anaesthesia and within the nominated age range (Section 2.2). Forty-four of 
these dogs were males scheduled for castration and 27 were females to undergo 
ovariohysterectomy. One male was cryptorchid.  
The dogs weighed an average 14.2 ± 11.2kg (mean ± SD, range 2.0 to 46.0kg).  
 
3.2 Group allocation 
According to the assessment of demeanour described above (Section 
2.5.1.2.1), a total of 24 dogs were given a score of either 3 or 4, and were placed into 
groups involving no premedication. The remaining 47 dogs were given scores of 1 or 
2, placing them into groups including premedication. The numbers allocated into the 
various groups is detailed in the table below (Table 3.1). The data from one dog in the 
sevoflurane induction after premedication group was discarded (Section 3.4.1), 
leaving thus a total of 8 dogs in this group. 
 
Maintenance agent 
 
Halothane Isoflurane Sevoflurane 
 NP P NP P NP P 
Intravenous 
induction 4 8 4 8 4 7 
Inhalant  
induction 4 7 4 8 4 9* 
 
Table 3.1   Experimental group allocation. 
  NP = No Premedication. 
P =Premedication.  
* Data from one dog discarded. 
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3.3 Prior to induction of anaesthesia 
Venipuncture was possible on all but four dogs without premedication. As part 
of the assessment of demeanour, these four exceptions were all placed into groups 
including premedication.  
Intravenous catheterisation of the left or right cephalic vein was successfully 
undertaken on all cases prior to induction of anaesthesia. In all cases, these catheters 
remained patent throughout the period of anaesthesia, and intravenous fluids were 
delivered as outlined above (Section 2.3.4).  
 
3.4 Induction of anaesthesia 
3.4.1 Inhalant inductions 
Of the 37 cases in inhalant induction groups, 35 were induced using the 
nominated agent. One dog in the (No premedication + Isoflurane) group and one in 
the (No premedication + Sevoflurane) group were induced with propofol following 
marked resistance to mask induction fulfilling the criteria of Section 2.3.3.1 for 
abandoning inhalant induction by mask. It should be noted that these two cases were 
excluded from the statistical analysis of induction time (Section 3.4.4). 
The first of these two dogs was a 15kg female young adult Blue Cattle Dog 
presented to the CDC for ovariohysterectomy. It was given a score of 3 for its 
demeanour (Section 2.5.1.2.1), and a score of 2 for tolerance of mask (Section 
2.5.2.2.1). It accepted the introduction of isoflurane to the circuit for 3min35sec 
before vigorously removing its head from the mask and requiring marked restraint to 
prevent its escape. Mask induction was abandoned and anaesthesia successfully 
induced with 90mg of propofol (6mg.kg-1) IV.  
The second dog was a 29kg male adult Golden Retriever. It was given a score 
of 3 for its demeanour and 3 for tolerance of mask. This dog cooperated with 
sevoflurane in the circuit for 1min45sec before responding in a similar fashion to the 
previously discussed case. Mask induction was abandoned and anaesthesia was 
induced with 175mg of propofol (6mg.kg-1) IV.  
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One male dog induced with sevoflurane after premedication was found to have 
an infected wound with abscessation. This dog was not desexed, and thus the data 
from this case was discarded.  
 
3.4.2 Intravenous inductions 
All 35 cases in intravenous induction groups were successfully induced using 
propofol according to the protocol in Section 2.3.3.2. 
 One dog withdrew and shook the catheterised foreleg upon administration of 
propofol, signs compatible with irritation from the administered drug. These signs 
were transitory, resolving in less than 10sec. The dog was in a group not receiving 
premedication. No other dog showed similar signs. 
 None of the 35 dogs showed the twitching or tonic-clonic type movements 
previously associated with propofol (Section 1.2.5.3). 
 
3.4.2.1 Propofol dose requirements 
Dogs induced with propofol after no premedication required significantly 
more propofol for intubation than those induced with propofol after premedication 
(4.32 ± 0.61mg.kg-1 (mean ± SE) vs 2.68 ± 0.24mg.kg-1; p = 0.0095 (two sample T 
test, untransformed data), p = 0.0074 (two sample T-test, transformed data), and 
p<0.01 (Mann-Whitney U test)).  
 
 
3.4.3 Intubation attempts 
 Fifty-nine of 71 dogs were intubated on the first attempt. Ten dogs 
required 2 attempts, the remaining two requiring three attempts. The initial attempt 
failed in only one dog due to incorrect endotracheal tube size selection.  
There was no association between experimental group and requirement for 
greater than one intubation attempt.  
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3.4.4 Time to intubation 
The time to endotracheal intubation in dogs anaesthetised with isoflurane by 
mask was significantly shorter than for those anaesthetised with halothane by mask 
(172.4 ± 15.0 vs 221.4 ± 14.0sec, p=0.021)(Table 3.2). 
There was no significant difference in time to intubation between dogs 
anaesthetised with sevoflurane by mask and those anaesthetised with halothane by 
mask (196.2 ± 14.8 vs 221.4 ± 15.0sec, p=0.207). Similarly, there was no significant 
difference in time to intubation between dogs anaesthetised with isoflurane by mask 
and those anaesthetised with sevoflurane by mask (196.2 ± 14.8 vs 172.4 ± 15.0sec, 
p=0.267).  
The time to endotracheal intubation in dogs anaesthetised with propofol by 
injection (85.4 ± 7.7sec) was significantly shorter than for those anaesthetised with 
halothane (221.4 ± 14.0sec), isoflurane (172.4 ± 15.0sec) or sevoflurane (196.2 ± 
7.7sec, p<0.001 in each case)(Figure 3.1).  
 Dogs induced with propofol after premedication had a significantly shorter 
time to intubation than those induced with propofol without premedication (59.5 ± 9.4 
vs 111.4 ± 12.6sec, p=0.002). In dogs induced with a gaseous agent, there was no 
significant difference in time to intubation between those not given premedication and 
those given premedication (halothane 225.6 ± 21.8 vs 217.2 ± 16.8sec, p= 0.757; 
isoflurane 176.8 ± 25.0 vs 168.1sec, p= 0.770; sevoflurane 222.6 ± 25.6 vs 169.7 ± 
14.4sec, p= 0.075). 
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All Cases No  Premedication Premedication 
 Mean SE Mean SE Mean SE 
Halothane 221.4* 14.0 225.6 21.8 217.2 16.8 
Isoflurane 172.4*,¶ 15.0 176.8 25.0 168.1 16.3 
Sevoflurane 196.2* 14.8 222.6 25.6 169.7 14.4 
Propofol 85.4¶ 7.7 111.4 12.6 59.5 9.4 
 
Table 3.2 Time to intubation (sec) 
* Significantly different from propofol (p<0.05). 
¶ Significantly different from halothane (p<0.05). 
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Figure 3.1: Time to intubation, in minutes 
Hal: Halothane 
Iso: Isoflurane 
Sevo: Sevoflurane 
Pro: Propofol 
 
 
67 
3.4.5 Quality of induction 
 An outline of quality of induction scores is shown in Table 3.3. A clear 
majority of all inductions (54 of 71) were scored as either of good or excellent quality. 
Data from the dog with abscessated wound was not considered. Due to operator error, 
two other cases were not given quality of induction scores.  
Dogs receiving premedication were 11.7 times more likely to be given an 
induction quality score of 4 than those not premedicated (OR 11.7, 95% CI: 2.7 – 
50.3). 
Dogs receiving propofol for induction were 4.4 times more likely to be given 
an induction quality score of 4 than those induced with a gaseous agent by mask (OR 
4.4, 95% CI: 1.3 – 14.2).  
In dogs that resisted the process of inhalant induction, it was commonly noted 
that signs of resistance commenced between 45 and 55sec after the inhalant entered 
the breathing circuit. 
 
Quality of induction Number of cases 
0 - Unacceptable 2 
1 – Poor 5 
2 – Fair 7 
3 – Good 24 
4 – Excellent 30 
        
Table 3.3 Quality of induction scores 
 
 
3.5  Intraoperative Variables 
A summary of the results for the measurement of mean arterial blood pressure, 
heart rate, end-tidal carbon dioxide and end-tidal anaesthetic concentrations is shown 
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in Table 3.4, broken down by gaseous anaesthetic agent and presence of 
premedication.  
The single mean value given for each of these variables in Table 3.4 was 
produced by pooling all measurements between 20min and 90min inclusive after 
commencement of induction. Specifically, readings from 20, 25, 30, 35, 40, 45, 50, 
55, 60, 70, 80 and 90min after induction were included for each variable.  
This single mean value was considered an acceptable representative for three 
reasons. By 20min after induction, the cardiorespiratory effects of propofol when used 
for induction should be effectively dissipated (Brussel et al. 1989; Ilkiw et al. 1992), 
avoiding any potential confounding effect. Secondly, the period 20min to 90min after 
commencement of induction represents the period with a appropriate quantity of data 
recordings. As can be seen in Figures 3.2 – 3.6, after 90min, some groups have two or 
less measurements, decreasing the validity of the data. In addition, particularly for 
measurement of mean arterial pressure, fewer readings were taken prior to 20min due 
to the time involved with placement of the intraarterial catheter. Thirdly, again 
referring to Figures 3.2 – 3.6 of the variables measured intraoperatively, the mean 
measurements between 20min and 90min remained relatively stable amongst most 
groups, making a single value a reasonable representation of the period.  
Based on these mean values, the decrease in required dose of inhalant between 
dogs not given premedication and those given premedication was 28.1% for 
halothane, 21.7% for isoflurane, and 1.8% for sevoflurane. 
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 All cases No premedication Premedication 
 Mean SD Mean SD Mean SD 
HR (beats.min-1) 
Hal 97.7 19.0 102.7 12.1 95.0 21.4 
Iso 106.7 16.1 111.4 17.4 104.0 14.7 
Sevo 103.9 21.1 101.9 17.6 105.2 23.0 
MAP (mmHg) 
Hal 78.6 16.3 75 14.1 81.1 17.3 
Iso 77.3 14.5 76.3 13.8 77.9 15.0 
Sevo 81.1 18.4 85.9 18.5 77.8 17.7 
ETCO2 (mmHg) 
Hal 42.9 7.0 44.0 8.5 42.2 5.8 
Iso 46.1 5.9 47.3 7.1 45.3 5.0 
Sevo 44.3 7.4 45.4 7.3 43.6 7.5 
ETAgent (vol%) 
Hal 1.11 0.35 1.36 0.30 0.98 0.31 
Iso 1.66 0.48 1.92 0.51 1.51 0.40 
Sevo 2.53 0.70 2.55 0.86 2.51 0.57 
ETAgent (MAC multiple) 
Hal 1.23 0.39 1.51 0.33 1.09 0.34 
Iso 1.29 0.37 1.49 0.40 1.17 0.31 
Sevo 1.14 0.32 1.15 0.39 1.13 0.26 
 
Table 3.4 Intraanaesthesia variables. Pooled values derived from all 
readings between 20 and 90min inclusive after induction.  
HR: Heart rate 
MAP: Mean arterial pressure 
ETCO2: End-tidal carbon dioxide concentration 
ETAgent: End-tidal inhalant agent concentration 
MAC: Minimum alveolar concentration (Section 1.1.4.1) 
1.MAC = 0.90vol% (Hal), 1.29vol% (Iso), 2.22vol% (Sevo) 
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  Figure 3.2:   Heart rate in dogs anaesthetised using halothane, isoflurane and sevoflurane, with and without 
premedication 
Columns:  Number of data recordings per experimental group, total of 70 dogs 
Lines: Mean values, heart rate 
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Figure 3.3:  Mean arterial pressure in dogs anaesthetised using halothane, isoflurane and sevoflurane, with and without 
premedication 
Columns:  Number of data recordings per experimental group, total of 70 dogs 
Lines: Mean values, Mean Arterial Pressure 
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 Figure 3.4: Mean end-tidal carbon dioxide concentrations in dogs anaesthetised using halothane, isoflurane and 
sevoflurane, with and without premedication 
Columns:  Number of data recordings per experimental group, total of 70 dogs 
Lines: Mean values, end-tidal carbon dioxide concentration 
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Figure 3.5: Mean end-tidal inhalant anaesthetic concentrations (vol%) in dogs anaesthetised using halothane, isoflurane 
and sevoflurane, with and without premedication 
Columns:  Number of data recordings per experimental group, total of 70 dogs 
Lines: Mean values, end-tidal inhalant concentration 
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 Figure 3.6: Mean end-tidal inhalant anaesthetic concentrations (MAC multiples) in dogs anaesthetised using 
halothane, isoflurane and sevoflurane, with and without premedication 
Columns:  Number of data recordings per experimental group, total of 70 dogs 
Lines: Mean values, end-tidal inhalant anaesthetic concentration (MAC multiple) 
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Figure 3.7 Oesophageal temperature at end procedure and its effect on recovery, in terms of time to righting 
(n = 69)
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3.6 Recovery from anaesthesia 
Of the 71 dogs enrolled in the study, 69 contributed data related to recovery 
from anaesthesia. Data from the dog not desexed due to an abscessated wound was 
discarded. The recovery data from one other dog, anaesthetised with isoflurane after 
premedication, was not used. Confusion as to whether this dog also required a 
supplementary surgical procedure led to recommencement of isoflurane 
administration for 3-4min, placing it outside the recovery protocol outlined in Section 
2.3.5.  
 
3.6.1 Time to righting 
The gaseous agent used for induction and maintenance of anaesthesia had no 
significant effect on the time to righting following anaesthesia.  
There was no significant difference in time to righting between dogs induced 
with propofol and those in which anaesthesia was induced with a gaseous agent.  
Dogs given premedication had significantly longer times to righting than those 
not given premedication (709.8 ± 58.3 vs 466.4 ± 48.6sec, p=0.003, Figure 3.8). 
Oesophageal temperature at end of procedure had a significant effect on time 
to righting (p=0.006), with lower temperatures leading to longer times to righting 
(Figure 3.7).  
Male dogs had significantly shorter times to righting than female dogs (498.2 
± 43.4sec vs 663.8 ± 69.9sec, p=0.05). The effect of sex on time to righting was not 
dependent on or modified by procedure time. Additionally, no significant interactions 
between sex and temperature were found.  
 
 
3.6.2 Time to standing 
The gaseous agent used had no effect on the time to standing after anaesthesia. 
The use of propofol for induction of anaesthesia had no significant effect on 
the time to standing after anaesthesia, in comparison to dogs induced with a gaseous 
agent. 
 77 
Dogs given premedication had a significantly longer time to standing than 
those not given premedication (1887.5 ± 189.1 vs 806.7 ± 84.9sec, p<0.001, Figure 
3.8). 
As for time to righting, male dogs stood significantly faster than female dogs 
(874.8 ± 96.4 vs 1742.4 ± 255.3sec, p = 0.001). Time of procedure had no significant 
effect on time to standing. 
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Figure 3.8 Effect of premedication on recovery from anaesthesia 
No PM: No premedication 
PM: Premedication 
 
 
 
3.7 Cost of induction and maintenance of anaesthesia 
The cost of induction with each of the three agents was calculated as described 
above (Section 2.7).  
Inhalant induction cost a mean of A$0.42, A$1.47 and A$7.94 for halothane, 
isoflurane and sevoflurane respectively. 
Intravenous induction with propofol after no premedication cost A$0.32 per 
kg body weight, A$4.59 for a dog of the mean weight in this study of 14.2kg, or 
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A$6.45 for a 20kg dog. When premedication was used, the reduced mean dose of 
propofol cost A$0.20 per kg body weight, A$2.84 for the 14.2kg animal, or A$4.01 
for a 20kg dog.  
Maintenance of anaesthesia, based on a vaporiser setting of 1.5.MAC for one 
hour with fresh gas flow of 1.0 l.min-1, cost A$0.64, A$4.01 and A$21.40 for 
halothane, isoflurane and sevoflurane respectively.  
Examples of reconditioned, agent specific precision vaporisers cost A$890, 
A$980 and A$1980 for halothane, isoflurane and sevoflurane respectively.  
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4.1 Introduction 
The purpose of this clinical trial was to compare, in the clinical environment, 
i) the relative merits of the newer gaseous anaesthetic, sevoflurane, to those of 
isoflurane and halothane, and, ii) to compare induction of anaesthesia with these 
agents to induction with the intravenous agent propofol. Previous evidence in the 
experimental environment indicated induction with sevoflurane by mask would be 
faster and of better quality than that occurring with isoflurane or halothane, and 
potentially be comparable to induction with propofol. 
 
4.2 Experimental design 
The design of this trial allowed comparison of anaesthesia, particularly 
induction and recovery, between the three different inhalant agents and one 
intravenous agent, in the clinical environment.  
The animals enrolled into this study were healthy adult dogs. Therefore the 
implications of this study should only be applied to a similar group of patients. The 
results occurring in other subgroups of patients in a normal veterinary practice, such 
as geriatrics, paediatrics and patients with systemic compromise from disease, may be 
considerably different. However, much of the growth in the use of inhalant induction 
in human practice has been in relatively healthy patients undergoing “day surgery”, 
and it is thus certainly justifiable to seek a better understanding of the effects of these 
agents in the equivalent group of veterinary patients. 
Given the clinical nature of this study, a crossover design, as has previously 
been used in studies of induction and recovery from inhalant agents, was not possible. 
Therefore, larger numbers of animals were required in order to provide a reasonable 
likelihood of revealing differences between the various groups. Calculations of 
statistical power suggested minimum group sizes of 4 animals would provide an 80% 
likelihood of revealing significant differences in induction time between the three 
inhalant agents. This was based on the magnitude of the differences reported in 
previous studies. Group sizes of at least 4 animals were achieved. However, the 
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presence of factors such as the clinical environment (Section 4.3) complicated the 
outcomes.  
It is perhaps worth speculating as to whether larger group sizes would have 
allowed more statistical differences to be discerned. Decreasing the total number of 
groups by decreasing the number of agents involved would have allowed larger 
numbers per group. This is further addressed below in relation to specific analyses, 
but overall, it would appear that very much larger group sizes would be required in 
order to produce differences between the various groups of statistical significance, if 
indeed such differences do exist.  
The lack of blinding was a shortcoming in this study. One investigator 
administered the agents and marked the scores for the qualitative data with knowledge 
of the experimental group into which the dog had been placed. This introduces an 
unpredictable element of bias into the qualitative data which can not be removed. 
However, full double-blinding of this trial was considered infeasible given staffing 
and time constraints.  
 
4.3 The clinical environment 
Understanding the differences between the clinical and experimental 
environments is crucial to rationalising the disparity in several areas between the 
results of the current study and previous studies of induction and recovery comparing 
sevoflurane with isoflurane and halothane. 
The methods used in this trial were designed to mimic circumstances found in 
a high quality private veterinary practice. The dogs were not acclimated to the 
induction room or procedures. During inhalant induction by mask, the maximum 
deliverable dose of the inhalant was used. It is common in clinical practice to use the 
maximum dose available from the vaporiser, in the assumption that the time to 
induction of anaesthesia will be minimised. As discussed below (Section 4.4.1.5), 
halothane was the main beneficiary of this dose selection. A previous experimental 
study of halothane and isoflurane induction in dogs could not discern a significant 
difference in speed of induction when equal concentrations, as opposed to equipotent 
doses, were used (Hellebrekers 1986). Although isoflurane is becoming more popular 
in private practice, halothane is still widely used and thus needed to be included in the 
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comparison. Dogs not receiving premedication were not given a placebo, likewise to 
mimic normal preanaesthetic procedure in a private veterinary practice. 
Desexing is a common surgical procedure. Despite the analgesic effects of 
meloxicam, and, in some dogs, morphine, the persistent noxious stimulation following 
the tissue trauma of surgery will influence recovery. This is an important factor in the 
recovery from anaesthesia in animals in the clinical situation. Restricting enrolment 
into this study to dogs undergoing these two procedures minimised the variation in 
recovery based on differences in noxious stimulation during surgery. Using these 
routine procedures also allowed the duration of anaesthesia to remain generally within 
a small range. 
In comparison, the two previous studies quantifying the differences between 
halothane, isoflurane and sevoflurane in dogs, in terms particularly of speed of 
induction and recovery, took place under very different circumstances. The studies by 
Mutoh, Nishimura et al. (1995) and Johnson, Striler et al. (1998) studies used Beagle 
dogs bred for research purposes. These dogs were anaesthetised more than once, as 
part of a crossover study design, and also in one study (Mutoh et al. 1995) for the 
placement of invasive monitoring equipment prior to the study proper. Although the 
full process of acclimation is not outlined in reports of these studies, the dogs 
involved were certainly given ample opportunity to become more accustomed to the 
procedure of inhalant induction of anaesthesia. This would likely decrease the 
psychological stress of the patient during inductions under study conditions. Lower, 
equipotent doses of inhalant were used, either 2.0.MAC (Johnson et al. 1998) or 
2.5.MAC (Mutoh et al. 1995). During the maintenance period of anaesthesia, no 
procedures were performed on the dogs, excluding the effect of noxious stimulation 
on recovery from anaesthesia. 
It is therefore likely the dogs of the current study were under more stress at the 
time of induction, and under greater levels of noxious stimulation during recovery. 
The effects of these factors are complex, and one can only speculate on the influence 
exerted upon the variables measured during this study. These factors may be 
considered as confounding factors, as they have made it more difficult to discern the 
effects of the inhalants themselves. However, the clinical environment represents the 
major area in which these agents are used, and therefore benefits seen only in the 
experimental situation may only be of limited value. 
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Whilst the disparity of these results, and specifically the inability of 
sevoflurane to display faster induction of anaesthesia than the older halogenated 
hydrocarbons, is no doubt due to many factors, the effect of the clinical environment 
stands tall above those areas discussed below. This issue represents a major hurdle for 
any new treatment introduced to veterinary practice. The uptake of sevoflurane by 
veterinarians, and particularly private practitioners, will no doubt be slowed if the 
experimental benefits of the newer, more expensive agent, can not make themselves 
clear in clinical patients. 
 
4.4 Induction of anaesthesia 
4.4.1 Time to induction 
4.4.1.1 Introduction 
The outcomes for time to induction of anaesthesia and quality of induction 
differed from what may have been expected. The greater speed of intravenous 
induction with propofol was in line with previous results. However, the lack of a 
significant difference in time to induction between those animals induced with 
sevoflurane by mask and those induced with either halothane or isoflurane was not 
consistent with two previous experimental studies.  
Faster induction of anaesthesia is advantageous to ensure rapid control of the 
airway, minimising the likelihood of complications such as aspiration of regurgitated 
stomach contents. The complicating effects of excitation during induction are 
minimised with shorter inductions. Rapid induction of anaesthesia is also convenient 
in busy clinical situations.  
 
4.4.1.2 Definition 
The time from commencement of the induction process until endotracheal 
intubation was considered the best available measure of time to induction of 
anaesthesia. This measure has been used previously in studies of anaesthetic induction 
(Mutoh et al. 1995; Johnson et al. 1998). It provides a functional measure of time to 
induction of anaesthesia. Other methods used in human anaesthesia for defining 
induction of anaesthesia, such as cessation of finger tapping (Smith and Thwaites 
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1999), dropping a weighted object (Thwaites et al. 1997) and loss of response to 
verbal command (Smith et al. 1992) are not usable in the veterinary context.  
 
4.4.1.3 Experimental group size 
As discussed in Section 4.2, the size of the experimental groups limited the 
ability to illustrate significant differences between these groups. In the case of time to 
intubation, the statistical analysis suggests considerably larger groups may well have 
been required to demonstrate such differences. As an example, the ANOVA 
comparison for time to induction between dogs anaesthetised with isoflurane and 
those anaesthetised with sevoflurane yielded a p-value of 0.267. This is well away 
from the suggested threshold for significance of p<0.05. 
 
4.4.1.4 Intravenous inductions 
Inductions with propofol were significantly faster than inductions with a 
gaseous agent. This correlates with data from a study in humans (Smith and Thwaites 
1999). Ultra-fast acting intravenous agents such as propofol or thiopentone possess a 
fundamental advantage over inhalant agents during induction in that a single bolus 
delivered over a few seconds can contain the entire dose required for completing 
induction of anaesthesia. This creates the most rapid rise in plasma concentrations 
possible, giving every opportunity for fast induction. Inhalant agents generally require 
many breaths over a period of a minute or more to deliver sufficient agent into the 
plasma and target tissues. In humans, the low solubility and relatively pleasant odour 
of sevoflurane make possible induction of anaesthesia from a single, large breath 
(Agnor et al. 1998). However, this procedure is not possible in dogs.  
 
4.4.1.5 Halothane dosage 
Higher doses of halothane were used for induction of anaesthesia in this study 
than have been previously used. The maximum output of a Tec 3 halothane vaporiser 
as used in this study is 5%, which equates to approximately 5.4.MAC for halothane. 
In comparison, doses of 3.8 and 3.4.MAC of isoflurane and sevoflurane respectively 
represented the maximum available output from the agent-specific vaporisers used. 
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As discussed above (Section 4.3), veterinarians commonly use the maximum output 
of the vaporiser during inhalant induction of anaesthesia via mask. There is no clear 
contraindication for using this dose of halothane during induction, provided that the 
patient is monitored to ensure the depth of anaesthesia does not become excessive in 
the minutes following intubation.  
The resultant times to intubation for halothane were significantly faster than 
those reported previously in comparisons with other agents. As an example, Mutoh, 
Nishimura et al. (1995) used 2.5.MAC halothane in unpremedicated dogs and 
recorded a mean time to intubation of 821.3sec. In the present study, unpremedicated 
dogs induced with halothane were intubated in a mean time of 225.6sec. Likewise, 
mean differences between halothane induction and isoflurane or sevoflurane induction 
of only 49 and 25sec respectively are considerably smaller than those reported using 
equipotent doses of the inhalants (Mutoh et al. 1995).  
 
4.4.1.6 Failed inhalant inductions 
Two dogs were placed into groups for inhalant induction without 
premedication but were unable to be satisfactorily induced with the selected agent. 
These posed certain problems. There was no satisfactory way to include these two 
cases in the statistical analysis of time to intubation. Although time to intubation was 
recorded for these cases, each was actually induced with propofol after some delay, 
and clearly this time bore no relation to those recorded for other animals in the same 
groups. Imputing a value for time to intubation for these dogs reflecting the slow, 
unsatisfactory induction of anaesthesia would have been artificial and impossible to 
undertake objectively. Therefore these two were excluded from the analysis, and the 
subsequent analysis results must be viewed with that point in mind.  
Thus it would appear that the analysis of time to intubation has been biased 
towards shorter times to intubation in the two groups in which failure of inhalant 
induction of anaesthesia occurred. The agents in these two cases were isoflurane and 
sevoflurane. The resultant analysis showed sevoflurane induction not to be 
significantly different from halothane or isoflurane inductions in terms of time to 
intubation. Thus the failed induction with sevoflurane should have no bearing on the 
validity of this result. Time to intubation for dogs induced with isoflurane was 
significantly faster than for those induced with halothane. The p-value for this 
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analysis being well below the threshold for significance, it is unlikely the omission of 
one failed induction with isoflurane affects the validity of this result. 
The implications of the two failed inductions with inhalant agents extend 
further than simply the statistical analysis. It would appear that in the clinical 
environment, not all dogs are suitable for induction of anaesthesia by an inhalant 
agent, particularly without premedication. A previous study of sevoflurane in clinical 
veterinary use described mask induction with this agent in 5 cases, however, no 
comment as to failed inductions, or the quality of inductions, was made (Haitjema and 
Cullen 2001).  
Both of these cases were in groups receiving no premedication. Both of these 
dogs, as well as the other 69 cases, submitted to the procedure of intravenous catheter 
placement prior to induction. The fact that these dogs were considered sufficiently 
calm on initial examination to be placed into no-premedication groups suggests that it 
may be difficult to determine before mask application which dogs will be unsuitable 
for inhalant agent induction. However, it should also be noted that these dogs 
originated from Blacktown Pound, and hence were potentially more likely to have 
underlying behavioural problems when restrained and handled. The success of 
inhalant induction of anaesthesia in a private practice environment will no doubt rest 
upon the population of animals on which it is used. 
 
4.4.1.7 Effect of premedication 
An improvement in speed of induction of anaesthesia was expected with the 
addition of premedication to the induction protocol, and was reflected in the results of 
the present study. However, the active selection of animals into groups for 
premedication makes interpreting these results somewhat more difficult. 
A basic assumption of the analysis of variance statistical method is that all 
animals have been randomly allocated into the experimental groups. Whilst this was 
the case for induction method and agent used in the current study, the dogs enrolled 
were not randomly allocated premedication. Dogs that were more excitable, nervous 
or hard to handle at the initial assessment of demeanour were placed into groups to 
receive premedication, those that were calmer were allocated to a group not receiving 
premedication (Section 2.5.1.2.1). Therefore, the effects shown in the statistical 
analysis as being due to premedication are not due to premedication alone, but also 
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due to the characteristics of the animals selected into the premedication groups. This 
should be considered when assessing the results. 
The use of acepromazine or morphine has been shown to decrease dose 
requirements for anaesthesia either with propofol or the inhalant agents (Pugh 1964; 
Raiha et al. 1989; Steffey et al. 1993). Lower dose requirements should be more 
rapidly achieved under the induction protocols used in the current study. Overall, 
animals premedicated showed a significantly faster time to intubation than animals 
not premedicated. However, when comparing the individual induction agents 
separately, only propofol showed a significant improvement with the addition of 
premedication. This may be indicative of the small group sizes of animals induced 
with inhalants without premedication, as compared to the larger number of dogs 
induced with propofol. 
Animals under more psychological stress at induction are expected to have 
slower and poorer quality inductions. It is therefore noteworthy that the group of 
animals exhibiting more signs of nervousness prior to anaesthesia was, after 
application of premedication to this group, the animals that were more rapidly 
induced. It would seem likely that had the premedication been randomly allocated, its 
effect may even have been stronger than shown in this study.  
 
4.4.1.8 Clinical significance 
The clinical significance of these results must also be considered. It is difficult 
to determine whether the mean 49sec difference between isoflurane and halothane in 
terms of time to intubation is of importance to the veterinarian administering the agent 
in private practice, especially given the lack of difference between the agents in terms 
of quality of induction. More so for sevoflurane, given that the mean time to 
intubation for the newest agent falls midway between the other inhalants. Although 
significantly faster for induction in the experimental environment, this study does not 
objectively identify any benefits to its use in the clinical situation for inhalant 
induction of anaesthesia, in the subgroup of healthy, young patients as enrolled 
herein. 
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4.4.2 Quality of induction 
The lack of significant difference between the inhalant agents in terms of 
quality of induction was unexpected. Expected, however, was the improvement in 
quality provided by premedication, and by induction with propofol over the inhalant 
agents. The clinical environment, as discussed above (Section 4.3), assumes a major 
role rationalising these results. Variations in each dog’s response to handling, 
intravenous catheter placement, placement of the induction mask, or other factors 
unknown, appear to assume greater importance than the variation between the three 
inhalants in terms of irritancy to the respiratory tract.  
Sevoflurane has previously been reported to give an improved quality of 
induction of anaesthesia over isoflurane in dogs (Johnson et al. 1998). It is suggested 
that this is due to sevoflurane’s lower irritancy to the respiratory tract, which leads to 
lesser decreases in tidal volume and minute volume on inhalation (Doi and Ikeda 
1993), combined with sevoflurane’s lower blood:gas solubility allowing faster 
changes in concentrations at the level of the CNS. The lack of difference between any 
of the three inhalants in the present study therefore demands explanation. 
 
4.4.2.1 Measuring quality 
All measures of quality of induction of anaesthesia are in essence subjective. 
The scale used to record this variable in this study has not been previously reported, 
although it is similar to that used by Johnson et al. (1998) in several of the behaviours 
on which the final score was based. Basing the score for quality of induction on 
several areas of behaviour exhibited by the animal provided more consistency to the 
scoring process. However, until the dog is able to converse on equal terms with the 
investigator to explain its experience of the process of induction of anaesthesia, all 
descriptions of quality of induction will be limited.  
More information on the animal’s response to induction may have been 
provided by the use of invasive monitoring of variables such as arterial blood pressure 
and oxygenation from before the commencement of induction. However, requiring 
previous general anaesthesia or at least deep sedation, placement of such 
instrumentation would not have been possible within the design of the study.  
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4.4.2.2 Effect of premedication 
The improvement in quality of induction in dogs receiving premedication over 
those not receiving premedication was expected. Premedication with agents such as 
acepromazine and morphine is commonly used for the specific purpose of improving 
the perceived quality of anaesthesia, as well as decreasing the induction agent doses 
required. Premedication should have decreased the psychological stress involved with 
induction of anaesthesia. The use of agents such as acepromazine prior to anaesthesia 
is also thought to minimise or completely remove the involuntary excitation phase of 
anaesthesia, with a consequent significant improvement in the perceived quality of 
anaesthesia. 
 
4.4.2.3 Intravenous inductions 
Inductions with propofol were of significantly better quality than inductions 
with an inhalant agent. Propofol inductions have been previously noted to completely 
bypass the excitation phase of anaesthesia (Watkins et al. 1987), and this was borne 
out in the results of the current study. However, a previous study in humans showed 
that anaesthetists blinded to the agent being used for induction of anaesthesia were not 
able to reliably judge whether sevoflurane by mask or a target-controlled infusion of 
propofol was being used (Smith and Thwaites 1999).  
No patients assigned propofol for induction failed to be satisfactorily 
anaesthetised with the intravenous agent, and propofol proved a satisfactory fall-back 
for those patients unable to be induced using inhalants. Although the necessity of 
intravenous access is sometimes considered a drawback, propofol remains a reliable 
agent for smooth, high quality induction of anaesthesia. 
 
 
4.5 Recovery 
4.5.1 Introduction 
An improvement in the speed and quality of recovery may have been expected 
in those animals maintained on the newer, less soluble inhalant agents isoflurane and 
sevoflurane. This was not borne out by the results. Reasons for these results cover 
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similar territory to that discussed under Sections 4.2 and 4.3. The improvement in 
speed of recovery, in terms of time to righting, with animals with higher body 
temperature, was a result with notable clinical significance. 
 
4.5.2 Time to righting and standing 
Several studies of recovery from anaesthesia in humans, as summarised by 
Patel and Goa (1996), indicate more rapid emergence following the use of 
sevoflurane, when compared to isoflurane in adults. Likewise, recovery in children is 
faster following the use of sevoflurane, compared to halothane. However, this has not 
been demonstrated in dogs, with Johnson, Striler et al. (1998) finding no difference 
between the recoveries of dogs anaesthetised with sevoflurane and those anaesthetised 
with isoflurane in a MAC determination study. This was supported by the current 
study, with the maintenance inhalant agent exerting no significant effect on recovery. 
These results indicate factors other than choice of inhalant agent exert the major 
influences on the speed and quality of recovery from anaesthesia in dogs.  
 
4.5.2.1 Duration of anaesthesia 
Within the range of procedure times recorded during this study, the duration of 
anaesthesia had no effect on the speed or quality of recovery. The mean time of 
anaesthesia, from induction to end procedure, was approximately 70min in this study. 
The choice of agent may have greater effect in procedures lasting considerably longer 
than this time, as it is likely the recovery from more soluble agents such as halothane 
is more elongated after such periods.  
 
4.5.2.2 Choice of induction agent 
The choice of either propofol or an inhalant agent for induction had no effect 
on the speed or quality of recovery. This is expected, as propofol is an ultra-short 
acting agent. Recovery in dogs given propofol sufficient only to induce anaesthesia 
was judged complete in approximately 20minutes (Watkins et al. 1987). The duration 
of anaesthesia in the current study was considerably longer. The residual effects of 
propofol should be minimal by this time, exerting a negligible effect on recovery.  
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4.5.2.3 Effect of premedication 
Anaesthetic protocols including the use of premedication led to significantly 
longer mean times to righting and standing in recovery. Given that the mean 
anaesthesia time in the current study was 70min, and dogs in the groups receiving 
premedication were given the acepromazine and morphine combination 
approximately 30min prior to induction, it was expected that both these drugs would 
still be exerting an effect on the animal during recovery. The effects of acepromazine 
and morphine are each expected to last 3 – 4hr (Pugh 1964; Branson and Gross, 
2001).  
In isolation, the tranquillising effects of acepromazine lead animals to assume 
“voluntary recumbency” (Pugh 1964), and therefore it is not surprising that dogs 
given acepromazine tended to take longer to stand after anaesthesia than dogs not 
given the drug. Animals experiencing discomfort postoperatively may stand or pace. 
Hence, dogs receiving the potent analgesic morphine would be less likely to show this 
behaviour postoperatively. 
From this, it becomes apparent that fast recoveries are not per se good 
recoveries. Animals that stand or move about soon after cessation of anaesthesia may 
in fact be demonstrating signs of pain, rather than benefiting from the rapid clearance 
of the anaesthetic agent. Adequate analgesia should not be withheld from a patient in 
order to produce a faster recovery.  
The clinical significance of the longer times to righting and standing after 
anaesthesia in the current study is likely very limited. The mean times to righting and 
standing for premedicated dogs were 709.8 and 1887.5sec respectively, or 11.8 and 
31.5min. These are relatively short periods, unlikely to interfere with the flow of work 
through a private practice or slow the discharge of a patient following desexing, and 
are probably indicative of the close attention paid to depth of anaesthesia and body 
temperature in these dogs. 
 
4.5.2.4 Effect of body temperature 
Although, in the personal experience of the author, dogs that become 
hypothermic have longer and poorer quality recoveries, no such study involving dogs 
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has been published. In the current study, animals which had lower body temperatures 
at the end of the procedure had significantly slower recoveries. Decreasing body 
temperature decreases the dose requirement for inhalant anaesthetics (Eger 1996). It 
should thus be expected that the time to recovery for hypothermic animals will be 
delayed. Hypothermia also slows the rate of metabolic processes within the liver and 
other tissues of the body, and decreases the minute respiratory volume (Mets 2000; 
Mallet 2002). Decreased body temperature may also depress cardiac function (Guyton 
1991; Mallet 2002). These effects will further slow the clearance of anaesthetic agents 
from the patient.  
Hypothermia is a major complication of surgery in small animals, particularly 
in the private practice situation. Conservation of body heat was a consideration within 
the design of this study, with the use of heat lamps on dogs after premedication and 
during recovery. Heat mats were used both during preparation for surgery, and 
surgery. The mean body temperature at end procedure (36.8 ± 0.8°C, mean ± SD) 
indicates these measures were generally successful. Nonetheless, even within this 
relatively benign range of body temperatures, a significant shortening of recovery 
time, in terms of time to righting, occurred with higher body temperature. It is likely 
that this effect would be even more pronounced with more extreme degrees of 
hypothermia. 
 
 
4.6 Intra-anaesthesia variables 
4.6.1 Biological significance 
Given the nature of the results recorded in relation to the cardiorespiratory 
variables measured during anaesthesia, further discussion should be preceded by 
consideration of their biological, or clinical, significance.  
Heart rate, end-tidal carbon dioxide and mean arterial blood pressure are 
variables measured frequently in clinical veterinary anaesthesia. As with all variables 
measured in veterinary science, ranges of values considered “acceptable” have been 
produced, reflecting the domain in which the patient is least likely to experience intra-
anaesthetic or post-anaesthetic complications. Acceptable heart rates are contingent 
upon the size of the dog, but may be considered as 60 – 140bpm. For end-tidal carbon 
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dioxide, the acceptable range used at the UVCC, and reflecting reports in the 
literature, is 35 – 50mmHg. For mean arterial blood pressure, 60 – 110mmHg.  
All mean readings for these three parameters for each of the three inhalants, as 
described in Table 3.4, are within these acceptable ranges. Therefore, it is difficult to 
ascribe any clinical significance to any of the differences between the three inhalants 
based on these results. Further statistical analysis of this data was thus considered 
unnecessary and potentially misleading.    
 
4.6.2 Heart rate 
Induction and maintenance of anaesthesia with sevoflurane has been 
previously associated with significant elevations in heart rate in comparison 
particularly to halothane (Harkin et al. 1994; Mutoh et al. 1995; Mutoh et al. 1997; 
Polis et al. 2001). Whilst Figure 3.2 indicates higher heart rates in the early minutes 
after induction, heart rates through the maintenance period of anaesthesia were similar 
for all three agents.  
The lack of obvious impact of the use of acepromazine and morphine as 
premedication should be noted. Both of these drugs have been shown to decrease 
heart rate (Popovic et al. 1972; DeSilva et al. 1978; Boyd et al. 1991; Kojima et al. 
1999), and it would be logical to consider that the analgesic effects of morphine 
would also produce lower heart rates during surgery. This was not noted, with the 
mean values for no-premedication and premedication groups for each inhalant being 
within one standard deviation of each other. 
Whilst anecdotal evidence indicates that heart rate increases at incision, this 
was not noted in the current results. This was most likely due to incision not occurring 
at a consistent time relative to induction, with the effect of incision therefore being 
spread over several data points. Further, with heart rate data collected only every 
5min, transitory increases may not have been recorded at all. 
 
4.6.3 End-tidal carbon dioxide concentration 
End-tidal carbon dioxide concentration was considered the most useful single 
indicator of respiratory function available within the limitations of the clinical 
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environment, as commonly used in previous studies (Mutoh et al. 1995; Steffey 1996; 
Mutoh et al. 1997). 
Isoflurane and sevoflurane have previously been shown to depress respiratory 
function more than halothane, in terms of ETCO2 readings (Mutoh et al. 1995; Steffey 
1996; Mutoh et al. 1997). Whilst values for ETCO2 in the current study tended to be 
slightly higher for isoflurane and sevoflurane than halothane, only one mean reading 
during the 20 – 90min maintenance period of anaesthesia exceeded the acceptable 
range for ETCO2 (Section 4.6.1), with the 40min reading for the group anaesthetised 
with isoflurane without premedication being 51.0mmHg. All other readings during 
this period remained within the 35 – 50mmHg acceptable range.  
Again, the lack of effect of premedication with acepromazine and morphine 
was noteworthy. Respiratory depression is an oft noted effect of morphine (Steffey et 
al. 1993). The lack of difference between the premedicated and non-premedicated 
animals in the current study may be due to the doses of morphine being considerably 
lower than those used in previous studies (Steffey et al. 1993), and to the confounding 
effects of the stimulus of surgery.  
 
4.6.4 Mean arterial blood pressure 
Whilst by no means the best single indicator, mean arterial blood pressure 
does illuminate elements of the health of the cardiovascular system under anaesthesia. 
MAP values were derived using the gold standard of intraarterial catheterisation. A 
more complete picture of the effects on the cardiovascular system by anaesthesia 
would have been produced by measurement of cardiac output, cardiac contractility 
and systemic vascular resistance. However, this would have required much more 
invasive testing, and was not compatible with the clinical nature of this study. 
MAP values have been shown to be generally lower with sevoflurane and 
isoflurane in comparison to halothane anaesthesia, although establishing statistically 
significant differences has eluded several studies (Steffey and Howland 1978; Bernard 
et al. 1990; Frink et al. 1992a; Murray et al. 1992; Harkin et al. 1994; Malan et al. 
1995; Mutoh et al. 1995; Holzman et al. 1996; Mutoh et al. 1997; Grosenbaugh and 
Muir 1998). In the current study, all three agents were closely grouped in terms of 
MAP values through the 20 – 90min segment of anaesthesia where the largest amount 
of data was available, and only one mean MAP point was below the minimum 
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acceptable range (Section 4.6.1) for MAP, with the 20min reading for dogs 
anaesthetised with isoflurane after premedication being 58.7mmHg.  
Again, the results indicated that the use of acepromazine and morphine had 
little effect on the MAP. Acepromazine has been variably associated with depression 
of MAP due to vasodilation (Popovic et al. 1972; Turner et al. 1974), and morphine 
should have similar effects (DeSilva et al. 1978; Given et al. 1986). Again, the effect 
of lower doses in comparison to previous studies, and the effects of surgical stimulus 
combine to produce the likely explanation for these results. 
 
4.6.5 End-tidal inhalant anaesthetic agent concentration 
Unlike the other intraanaesthesia variables measured, end-tidal inhalant 
anaesthetic concentrations (ETA) are not a measure of the animal’s physiological 
status under anaesthesia. ETA instead is the most accurate clinical means of 
determining the dose of the inhalant that is acting upon the patient. As expected, these 
readings varied widely between the three different agents. 
Halothane is a more potent anaesthetic agent than isoflurane, which in turn is 
more potent than sevoflurane. A higher concentration of a less potent agent must be 
delivered to provide the same effects in comparison to a more potent agent. The 
differing potencies of the three agents are reflected in their MAC values (Table 1.2). 
The dose requirement for normal surgery is expected to be at least 1.2 to 1.4.MAC 
(Steffey 1996). The MAC is influenced by many factors, the presence of drugs other 
than the inhalant and the core temperature of the animal being the most important 
factors in the current study. 
The mean ETA values measured in the current study for dogs anaesthetised 
with halothane or isoflurane without premedication represented 1.51 and 1.49 times 
previously established values for MAC for the respective agents. In those patients 
induced with propofol, it would be expected that the influence of this drug should 
have passed by 20min after induction, the time from whence measurements of ETA 
were used for these calculations. Approximately 1.5.MAC is in line with the 
previously discussed requirements for normal surgery in dogs (Steffey 1996). 
However, patients anaesthetised with sevoflurane without premedication required 
only a mean of 1.15.MAC over the same period. 
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Acepromazine and morphine  have each been shown to decrease the MAC for 
isoflurane or halothane by more than 40% (Heard et al. 1986; Steffey et al. 1993).  
Patients anaesthetised with halothane or isoflurane after premedication required 
28.1% or 21.7% less of the respective inhalant than those not premedicated. Again, 
these results were in line with expectations from previous literature on depression of 
MAC by these agents. However, there was effectively no change in the concentration 
of sevoflurane required by premedicated animals, at 2% less than non-premedicated 
animals.  
The lower overall requirement for sevoflurane, in comparison to its 
established MAC value, and the lack of reduction of sevoflurane dose requirement 
following premedication is somewhat of a mystery to the author. There is no obvious 
explanation. Operator bias could potentially be involved, possibly involving closer 
examination of the depth of anaesthesia and vaporiser settings when using the less 
familiar agent. This, however, can only be speculation. 
 
 
4.7 Financial considerations 
 Private veterinary practice is sensitive to costs involved in anaesthesia. As 
outlined above, the newer inhalant agents increase the overall cost of anaesthesia due 
both to their increased price per unit volume, and their higher dose requirements, 
compared to halothane. Whether this cost can be absorbed into charges passed onto 
the client in normal veterinary practice will vary greatly between practices, and is 
beyond the scope of this thesis to discuss. However, it is evident that the lack of clear 
advantage to the use of an agent such as sevoflurane in routine cases, such as 
desexing, would make many private practitioners loth to purchase the more expensive 
product.  
The impact of the much greater cost of the sevoflurane vaporiser in 
comparison to those for halothane or isoflurane will vary widely between practices, 
based on the number of cases seen and overall financial arrangements. 
The maintenance of anaesthesia costs outlined above should be used primarily 
for comparison between the agents, and will in many cases overestimate the actual 
consumption of inhalant. In the current study, the minimum fresh gas flow of 1.0 
l.min-1 was used due to the loss of at least 500ml.min-1 to the monitoring equipment. 
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With more efficient monitoring, a minimum gas flow of 500ml.min-1 is quite 
acceptable in a rebreathing system, provided this supplies at least 20ml.kg.min-1 
(Steffey 1996).  Such a gas flow rate would immediately halve the described 
maintenance cost. Premedicated animals in the current study were often able to be 
maintained on vaporiser settings equal to less than 1.5.MAC for the specific agent, 
similarly reducing the cost of the agent for maintenance of anaesthesia. During the 
transition phase from an intravenous induction to a inhalant maintenance of 
anaesthesia, vaporiser settings when using the more insoluble isoflurane and 
sevoflurane may be more rapidly decreased to a maintenance level, due to the more 
rapid rise in target tissue concentrations with these agents. This in turn would 
decrease the cost of these agents relative to halothane.  
Despite these considerations, it may be assumed that sevoflurane will retain a 
considerable cost premium over the older agents for the foreseeable future. 
 
 
4.8 Conclusion 
This study was undertaken to test four hypotheses as outlined in Section 1.6. 
Essentially these focussed upon elucidating the differences between halothane, 
isoflurane, sevoflurane and propofol when used for induction and maintenance of 
anaesthesia in dogs undergoing the common clinical procedure of desexing.  
Previous studies of human and veterinary anaesthesia indicated that mask 
induction using sevoflurane resulted in significant advantages in terms of the speed 
and quality of induction, when compared to either halothane or isoflurane. Likewise, 
the medical literature points towards faster recoveries with the newer agent. Such 
results are in line with the basic chemical properties of these agents. However, the 
veterinary literature is limited in comparison to the medical literature, with no 
quantitative, comparative studies of this topic undertaken in the clinical context.   
This study showed no advantages for the use of sevoflurane over either 
halothane or isoflurane. The speed of induction using sevoflurane was not 
significantly different from that seen with either halothane or isoflurane. Induction of 
anaesthesia using isoflurane by mask was significantly faster than induction using 
halothane by mask. Choice of inhalant for induction did not improve the quality of 
induction, as perceived by the veterinarian administering the agent. However, the use 
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of propofol was associated with significantly faster inductions and an improved 
quality of induction. During the maintenance phase of anaesthesia, standard 
cardiorespiratory variables remained within normal ranges for all three inhalants. 
Speed of recovery from anaesthesia was not affected by choice of inhalant or 
induction method, but was increased by improving core temperature at the end of the 
procedure. The use of premedication slowed the time to righting and standing. 
All studies are limited. The current study involved a total of 12 experimental 
groups, a result of comparing three different inhalants and one intravenous agent. This 
produced smaller numbers in each group, limiting the ability to detect significant 
differences between the groups. Although the importance of this problem is 
questionable, further study focussing on comparing, for example, isoflurane and 
sevoflurane in premedicated dogs would improve the power of the resultant analysis. 
Blinding of the person delivering the induction agent and the person assessing the 
quality of induction and recovery would assist in removing bias.  
Importantly, the results of this study should not be extrapolated to other 
groups of patients anaesthetised in clinical practice. Further studies remain to be 
undertaken within the clinical context to examine the benefits of the newer inhalants 
in such areas as paediatric patients, geriatric patients, and patients compromised by 
systemic disease or trauma. Recovery from anaesthesia may be significantly improved 
using the newer agents when patients are anaesthetised for considerably longer than 
the mean 70min occurring in the current study.    
The variance between these results and those previously reported is likely to 
be primarily due to the clinical environment. A dog handled by strangers in an 
unusual environment will respond to the induction agent somewhat differently to a 
dog acclimated to its surroundings, the staff, and the procedure. In the clinical 
situation, the former case is the usual. In an analysis of the differences between 
induction agents, these unpredictable responses may be considered confounding 
factors, as the influence of the specific agent becomes harder to discern. However, it 
is difficult to recommend the use of a particular agent in the clinical situation if the 
theoretical advantages of that agent can not be demonstrated in the clinical 
environment.  
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